



**Transient neurological symptoms in the older population:
Report of a prospective cohort study - the Medical Research
Council Cognitive Function and Ageing (CFAS) Study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003195
Article Type:	Research
Date Submitted by the Author:	09-May-2013
Complete List of Authors:	Mavaddat, Nahal; University of Cambridge, Department of Public Health and Primary Care Savva, George; Trinity College Dublin, Medical Gerontology Lasserson, Daniel; University of Oxford, Primary Care Health Sciences giles, matthew; Biomedical Research Centre, John Radcliffe Hospital, Stroke Prevention Research Unit, Brayne, Carol; University of Cambridge, Institute of Public Health Mant, Jonathan; University of Cambridge, General Practice and Primary Care Research Unit
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Cardiovascular medicine, Epidemiology
Keywords:	Stroke < NEUROLOGY, EPIDEMIOLOGY, Stroke medicine < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts

only

1
2
3
4 **Transient neurological symptoms in the older population: Report of**
5 **a prospective cohort study - the Medical Research Council Cognitive**
6 **Function and Ageing Study (CFAS)**
7
8
9

10
11 **Nahal Mavaddat, George M Savva, Daniel Lasserson, Matthew**
12 **Giles, Carol Brayne, Jonathan Mant**
13

14
15
16
17 **Department of Public Health and Primary Care, University of**
18 **Cambridge, Strangeways Laboratory, Worts Causeway, Cambridge,**
19 **UK CB1 8RN Nahal Mavaddat clinical lecturer Jonathan Mant**
20 **professor The Irish Longitudinal Study on Ageing, Department of**
21 **Gerontology, Trinity College Dublin, Lincoln Gate, Dublin 2,**
22 **Republic of Ireland George Savva lecturer Department of Primary**
23 **Care Health Sciences, University of Oxford, Oxford, U.K. New**
24 **Radcliffe House, 2nd floor, Walton Street, Jericho, UK OX2 6NW**
25 **Daniel Lasserson clinical lecturer Stroke Prevention Research Unit,**
26 **NIHR Biomedical Research Centre, Oxford University, Department**
27 **of Clinical Neurology, John Radcliffe Hospital, Oxford, UK OX3**
28 **9DU Matthew Giles consultant physician**
29 **Department of Public Health and Primary Care, University of**
30 **Cambridge, Institute of Public Health, Forvie Site, Robinson Way**
31 **Causeway, Cambridge, UK CB2 0SR Carol Brayne professor**
32
33
34
35
36
37

38
39 **Correspondence to: Nahal Mavaddat nm212@medschl.cam.ac.uk**
40
41
42

43
44 The Corresponding Author has the right to grant on behalf of all authors and does
45 grant on behalf of all authors, an exclusive licence (or non exclusive for government
46 employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this
47 article (if accepted) to be published in BMJ editions and any other BMJ PGL products
48 and sublicences such use and exploit all subsidiary rights, as set out in our licence.
49
50
51
52
53
54
55
56
57
58
59
60

Article Summary

Article Focus:

- Prompt initiation of secondary prevention following TIA is associated with up to 80% reduction in risk of subsequent stroke.
- Many people presenting to specialist TIA clinics with transient neurological symptoms do not have TIA.
- The prevalence and incidence of transient neurological symptoms (as opposed to TIA) in older age groups is unknown.

Key Messages:

- In a large multi-centred community based study representative of the older population in the UK we found a high prevalence and incidence of transient neurological symptoms, significantly greater than that of TIAs.
- This highlights the need for adequate provision of TIA services and better diagnostic tools, especially as the public becomes more sensitised to possible cerebrovascular symptoms, and primary care practitioners more aware of the potential benefits of rapid response to suspected TIA.

Strengths and Limitations of this study:

- Strengths - Previous studies of incidence and prevalence of transient neurological symptoms have mostly been conducted in populations not representative of older age groups where TIA is most common and few have been undertaken in UK populations.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Limitations - The incidence of transient neurological symptoms in the study was determined in people without severe cognitive impairment, and may be an underestimate since cognitive impairment can be a manifestation of vascular disease. The wording of questions to identify transient neurological symptoms may have picked up some people who had symptoms lasting more than 24 hours. Such patients are nevertheless likely to draw on TIA services for further assessment.

ABSTRACT

Objective: Transient ischaemic attack (TIA) is a recognised risk factor for stroke in the older population requiring timely assessment and treatment by a specialist. The need for such TIA services is driven by the epidemiology of transient neurological symptoms, which may not be caused by TIA. We report prevalence and incidence of transient neurological symptoms in a large UK cohort study of older people. **Design** Longitudinal cohort study **Setting and Participants:** The MRC Cognitive Function and Aging Study (CFAS) is a population representative study derived from random samples of people in their 65th year. Interview at baseline included questions about stroke and transient neurological symptoms, repeated in a sub-sample after two years. Patients were flagged for mortality. **Main Outcome Measures** Prevalence and two year incidence of transient neurological symptoms. **Results** In 11,903 participants without history of stroke, 271(2.3%) reported transient problems with speech, 872 (7.6%) with sight, and 596 (5.1%) weakness in a limb, with 1456 (12.7%) reporting at least one symptom. Of those re-interviewed (n=6748), 675 (9.8%) reported at least one symptom over two years. **Conclusions** Lifetime prevalence and incidence of transient neurological symptoms in people 65 and over is substantially higher than incidence of TIA in hospital and population-based studies. With increasing public education regarding stroke, TIA services may need to cope with an increase in demand as a greater proportion of people with transient neurological symptoms present for urgent assessment.

INTRODUCTION

Transient ischaemic attack (TIA) is an established and powerful risk factor for stroke. 8% of patients who have a TIA suffer a stroke within 7 days, many within 48 hours.^{1,2} Immediate specialist assessment and treatment is associated with substantial reductions in this early risk of stroke,³ and is recommended for people with suspected TIA.⁴

As awareness grows of the urgency of early management of TIA amongst both primary care practitioners and the general public,⁵ more patients with symptoms suggestive of a TIA are likely to present to primary and secondary care services. Need for specialist services will be driven by incidence of symptoms that might represent TIA (i.e. transient neurological symptoms) rather than the epidemiology of TIA *per se*. Currently about 48,000 probable or definite TIAs (transient neurological symptoms lasting less than 24 hours of likely vascular aetiology), and 43,000 minor strokes (stroke events causing minimal or no neurological deficits) are managed as outpatients every year in England, but it is not clear to what extent this might be the tip of the iceberg.⁶ Data are available worldwide on the prevalence and incidence of TIA.⁷⁻¹¹ The epidemiology in the community of transient neurological symptoms (i.e. neurological symptoms of sudden onset of which TIA is a subset), is however less well defined. Previous studies of incidence and prevalence of transient neurological symptoms, have mostly been conducted in populations not representative of older age groups where TIA is most common.^{7;11-16} Very few have been undertaken in UK populations. While incidence of transient neurological symptoms will drive need for

1
2
3 specialist TIA services, prevalence of transient neurological symptoms in the
4
5 community is also important. TIA is associated with a long term increase in risk of
6
7 stroke,^{17;18} so there may be value in diagnosing 'old' events that have not presented
8
9 to medical services in order to target secondary prevention. Hence the need to know
10
11 both the incidence and prevalence of transient neurological symptoms in the
12
13 community.
14

15
16
17
18 This study reports prevalence and incidence of three common transient neurological
19
20 symptoms (limb weakness, loss of speech and disturbance of vision) in a population
21
22 based multi-centred cohort study in the UK (England and Wales) in those aged 65 and
23
24 over, the Medical Research Council Cognitive Function and Ageing Study (CFAS).¹⁹
25
26
27

28 29 **METHODS**

30
31 The Medical Research Council CFAS is a population based study of individuals aged
32
33 65 years and over living in the community. The study began in 1991 and was
34
35 designed to determine the incidence of dementia in the older population. It has six
36
37 centres across England and Wales chosen to represent the national variation of urban-
38
39 rural mix, socio-economic deprivation and rates of chronic disease.¹⁹ Five of these
40
41 with identical study designs (Oxford, Nottingham, Cambridgeshire Gwynedd and
42
43 Newcastle) are used in the present investigation. The sixth centre (Liverpool) used a
44
45 different design and is therefore excluded. Random samples of people in their 65th
46
47 year and above were obtained from Family Health Service Authority lists (agency
48
49 responsible for maintaining registers of general practice populations at that time). The
50
51 sample was stratified by age (65-74, and 75 years and over) and equal numbers were
52
53 randomly selected from these groups with the aim of recruiting 2500 to each centre.
54
55
56
57
58
59
60

1
2
3 All study centres obtained ethical approval from local research committees. (REC
4
5 Ref: 05/MRE05/37). Full details of methodology are available elsewhere.¹⁹
6
7

8 Eligible participants provided informed consent (or their proxies where appropriate).
9
10 Trained interviewers undertook baseline interviews in the participants' homes
11 including socio-demographic characteristics, cognitive function and disease history
12 including previous stroke, coronary heart disease and diabetes (full details at
13 www.cfas.ac.uk). Based on baseline screening, the study sample was divided into two
14
15 groups at baseline: people without cognitive impairment and a group consisting of
16
17 those with cognitive impairment plus a stratified subsample of those without
18
19 cognitive impairment. The first group underwent no further assessment at baseline
20
21 and were 'rescreened' after two years. The second group underwent a further detailed
22
23 cognitive assessment at baseline, but were not followed up for transient neurological
24
25 symptoms. The estimates of prevalence of transient neurological symptoms are
26
27 calculated for all people at baseline, while the incidence estimates use only the first
28
29 group. All participants were flagged with the NHS Central Register. Deaths and
30
31 underlying causes of death attributed to stroke (ICD codes 430-438) were notified to
32
33 the study.
34
35
36
37
38
39
40
41
42

43 *Prevalence of transient neurological symptoms*

44
45 At baseline all participants were asked "Have you ever experienced sudden problems
46
47 with:
48

49
50 (1) speech, which got better after a day?
51

52
53 (2) weakness in the arms or legs, which got better after a day?
54

55
56 (3) sight, which got better after a day?"
57
58
59
60

1
2
3 Social class was determined using the Registrar General's Occupational
4 Classification. Cognitive status was determined using the Mini Mental State
5 Examination (MMSE),²⁰ and the Automated Geriatric Examination for Computer
6 Assisted Taxonomy (AGECAT).²¹
7
8
9
10

11 *Incidence of transient neurological symptoms*

12
13 All those in the 'rescreen' arm were asked at two year follow-up if they had
14 experienced each transient neurological symptom in the past two years.
15
16
17
18
19

20 **Analysis**

21
22 All analyses were carried out using STATA version 11. Inverse probability weights
23 were used throughout to ensure the sample was representative of the target
24 population. Weights were estimated with logistic regression using presence in each
25 phase of the study as an outcome and taking into account over-sampling of over-75s
26 at baseline. Weights for incidence calculations adjust for attrition based on baseline
27 characteristics and stratified selection into the assessment arm as appropriate.
28
29 Baseline prevalence of each transient neurological symptom was calculated for age
30 specific strata and as a weighted percentage to provide a population estimate of
31 prevalence for people aged 65 and over. Associations with gender, age, social class
32 (manual (IIIb, IV, V) and non-manual (I, II, IIIa)), and cardiovascular comorbidity
33 were explored using logistic regression models adjusting for all other factors and
34 cognitive function based on MMSE by score (less than 18, 18-21, 22-25 and 26-30).
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51
52 Two year incidence of transient neurological symptoms was estimated using weighted
53 percentages of those reporting any of the symptoms during follow-up. Weights were
54 adjusted for refusals, drop-outs and for non-reassessment of people with cognitive
55
56
57
58
59
60

1
2
3 impairment. Calculation of attrition weights for incident transient neurological
4 symptoms excluded those who died between baseline and follow up. These estimates
5 are therefore applicable to the population over 65 without severe cognitive
6 impairment or stroke at baseline surviving at least two years.
7
8
9
10

11 12 13 **RESULTS**

14
15
16 The participation rate in the CFAS study was 80% (13,004/16,258). For the
17 prevalence analysis, participants who had a stroke at baseline (963, 7.4%) or for
18 whom baseline information about stroke was missing (138, 1.1%) were excluded,
19 leaving 11903 participants. 2,283 of the original participants were not allocated to the
20 'rescreen' arm at two years; 754 died, 1973 declined to participate and 145 were lost
21 to follow-up, leaving 6,748 (76% response rate of potential participants) for the
22 incidence analysis.
23
24
25
26
27
28
29
30
31

32
33 Table 1 shows the demographic features of participants in the CFAS studied in this
34 analysis at baseline. 40% of participants were male and 60% of participants were
35 female. 12.3% of all participants reported at least one transient neurological
36 symptom. 2.3% reported transient loss of speech, 5.1% transient weakness and 7.6%
37 transient loss of sight.
38
39
40
41
42
43
44
45

46 Table 2 shows prevalence data with weighted percentages and odds ratios (adjusted
47 for age, sex, social class, cognition and cardiovascular morbidities) of reported
48 transient neurological symptoms at baseline by demographic factors and
49 comorbidities. 12.8% of males and 12.0% of females reported at least one of the three
50 transient neurological symptoms of loss of speech, loss of sight, or weakness. There
51 was no significant association of gender with reporting at least one transient
52
53
54
55
56
57
58
59
60

1
2
3 neurological symptom, but a significantly lower odds of reporting a transient
4 neurological symptom in the over 85 age group. Problems of memory and recall may
5 have contributed to under-reporting in this group. Greater rates of mortality
6 associated with neurological incidents in the oldest old population may also lead to
7 under estimation of rates of transient neurological symptoms. The odds of reporting
8 any transient neurological symptom were higher in those in manual compared to non-
9 manual social classes. The presence of cardiovascular morbidities of angina and heart
10 attack were significantly associated with the odds of having at least one of the
11 transient neurological symptoms.
12
13
14
15
16
17
18
19
20
21
22
23
24

25 There was no difference between genders with regards to reporting individual
26 transient neurological symptoms of loss of speech, loss of sight or weakness.
27 However, there was a significantly lower odds of reporting transient visual loss in
28 those over 85. This may partly explain the overall lower prevalence of reporting at
29 least one transient neurological symptom in this group. The cause for this is unclear,
30 however in addition to problems of recall, may in part relate to the greater likelihood
31 of chronic visual problems potentially masking transient visual losses in the oldest old
32 population. There was an increased odds of reporting transient symptoms of weakness
33 and loss of sight in manual compared to non-manual social classes. The presence of
34 cardiovascular co-morbidities of angina and heart attack were associated with higher
35 odds of all three symptoms.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Table 3 shows two year incidence of transient neurological symptoms in respondents
52 attending the “rescreen”. 9.8% of all participants reported at least one transient
53 neurological symptom over the 2 years, with the highest incidence of reported
54
55
56
57
58
59
60

1
2
3 transient neurological symptom being due to loss of sight followed by weakness, with
4 loss of speech being the least frequently reported transient neurological symptom. The
5 incidence of each of the transient neurological symptoms was highest in the 75 to 84
6
7
8
9
10 age group and lowest in the over 85 age group.

14 DISCUSSION

15
16
17
18 Our findings suggest that transient neurological symptoms are common in the older
19 population in England and Wales, with at least 12% of people aged 65 and over
20 having experienced a transient neurological symptom of the arm or leg, speech or
21 vision better after a day, and approximately 5% experiencing at least one such
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
220

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

^{14;16} Questions used to elicit transient neurological symptoms in the CFAS are likely to have captured greater numbers of transient neurological events in the population compared to those seeking more specific vascular symptoms, or to the few studies defining more precisely the onset, offset and timing of the event. ^{7;12-14} While some respondents will have been describing true transient ischaemic events, it is likely that many did not have a true TIA. Validated measures to determine the presence of previous transient ischaemic attack are limited, and most studies of transient neurological symptoms in questionnaires overestimate true transient ischaemic attacks. ^{13;14;22} Wilkinson et al. (1979) suggest that around 10% of transient symptoms reported in a questionnaire are subsequently diagnosed as TIA after neurologist assessment. ¹⁴ Self-reported transient neurological symptoms in other community based studies have low positive predictive value, with higher values only in studies in outpatient populations (over 70%). ^{13;14;22-24} This suggests that the use of screening to identify possible past transient ischaemic attacks may generate unnecessary extra strain on primary care and secondary TIA services with limited benefit.

Patients presenting with transient neurological symptoms present considerable diagnostic dilemmas for primary care practitioners reflected in low rates of TIA diagnosis confirmation in patients referred to UK TIA clinics (over 50% being for non-TIA causes). ²⁵⁻²⁷ Many symptoms of TIA are non-specific and occur in non-vascular syndromes. Dizziness, ophthalmological problems, migraine, epilepsy, nerve entrapment or psychological states are the commonest non-TIA diagnoses. ^{25;26;28-30} Often, however, no diagnosis can be determined. ^{25;26} Scales such as the ABCD2 ² help determine the urgency of TIA referral, but do not distinguish TIA from non-TIA symptoms. Wilkinson et al. reported transient loss of speech and loss of sight to be

1
2
3 more reliable than limb weakness for neurologist diagnosis of TIA,¹⁴ while Hart et al.
4
5 found the strongest and most consistent relationship with subsequent stroke to be loss
6
7 of power in an arm.⁷ Other studies suggest that the presence of certain symptoms such
8
9 as headache, dizziness, loss of consciousness, memory loss, blurred vision,
10
11 generalised weakness, pain in limbs and seizures make the diagnosis of TIA less
12
13 likely.^{14;30;31}

18 Study limitations

20 The incidence of transient neurological symptoms in the CFAS was determined in
21
22 people without severe cognitive impairment, and may be an underestimate since
23
24 cognitive impairment can be a manifestation of vascular disease.^{32;33} Some symptoms
25
26 of TIA (e.g. posterior circulation or pure sensory symptoms) were not sought in the
27
28 CFAS. The wording of questions to identify transient neurological symptoms may
29
30 have picked up some people who had symptoms lasting more than 24 hours. Such
31
32 patients are nevertheless likely to draw on TIA services for further assessment. In
33
34 addition, it was not possible to determine whether different transient neurological
35
36 symptoms in a participant occurred simultaneously or separately in time. The problem
37
38 of recall bias in these self-reports of transient symptoms needs to be considered.
39
40 Finally, baseline and two year follow-up were carried out in the 1990s and changes in
41
42 rates of vascular events may have occurred since then. While the age-specific
43
44 incidence of stroke appears to be declining, it is not clear that the same is true of TIA.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10;34;35 As well, this study is more recent than many studies estimating rates of
transient neurological symptoms in the population, many of which have been carried
out during the 1970's or '80's.¹²⁻¹⁴

Conclusion

In a large multi-centred community based study highly representative of the older population in the UK and conducted in the age group where TIAs are most common, we found a high prevalence and incidence of transient neurological symptoms. The incidence of such symptoms in the community is significantly greater than that of TIAs, suggesting that potential demand for TIA clinics where a confirmation of TIA diagnosis is made by a specialist, might rise significantly in the future as the public becomes more sensitised to possible cerebrovascular symptoms, and primary care practitioners more aware of the potential benefits of rapid response to suspected TIA. This highlights the need for adequate provision of TIA services and the potential importance of the development of valid diagnostic tools to assist the general practitioner and hospital doctor in better triage of people presenting with transient neurological symptoms.

ACKNOWLEDGEMENTS

We thank the MRC CFAS study group for data collection and management. We are also grateful to all respondents, their families and their primary care teams from across the country for their participation in the CFAS.

COMPETING INTERESTS

"All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have

1
2
3 an interest in the submitted work in the previous three years; no other relationships or
4
5 activities that could appear to have influenced the submitted work."
6
7

8 9 **FUNDING**

10
11 The MRC CFAS Study has had funding by major awards from the Medical Research
12 Council (MRC/G9901400) and Department of Health. NM was funded by a National
13 Institute for Health Research (NIHR) Walport Clinical Lectureship in Primary Care
14 Research. None of the sponsors influenced the design or conduct of the study or the
15 analysis or interpretation of the findings. All researchers acted independently from
16 funders in the design and carrying out of this study.
17
18
19
20
21
22
23
24
25
26
27
28
29

30 31 **AUTHORS CONTRIBUTIONS**

32 CB is Principal Investigator of the MRC CFAS Study. NM and GS contributed to
33 analysis of data. All authors contributed to study design and intellectual input. All
34 authors, external and internal, had full access to all of the data (including statistical
35 reports and tables) and can take responsibility for the integrity of the data and
36 accuracy of the data analysis.
37
38
39
40
41
42
43
44
45

46 47 **DATA SHARING**

48 Data sharing through application.
49
50
51
52
53
54
55
56
57
58
59
60

Reference List

- 1
2
3
4
5 (1) Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of
6 stroke after transient ischaemic attack or minor stroke: implications for public
7 education and organisation of services. *BMJ* 2004; 328(7435):326.
8
- 9
10 (2) Rothwell PM, Giles MF, Flossmann E, Lovelock CE, Redgrave JN, Warlow
11 CP et al. A simple score (ABCD) to identify individuals at high early risk of
12 stroke after transient ischaemic attack. *Lancet* 2005; 366(9479):29-36.
13
- 14 (3) Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O,
15 Redgrave JN et al. Effect of urgent treatment of transient ischaemic attack and
16 minor stroke on early recurrent stroke (EXPRESS study): a prospective
17 population-based sequential comparison. *Lancet* 2007; 370(9596):1432-1442.
18
- 19 (4) Department of Health . Department of Health. National Stroke Strategy. 7.
20
- 21 (5) Department of Health. Stroke: Act F.A.S.T. awareness campaign. 2009.
22 Department of Health.
23
- 24 (6) Giles MF, Rothwell PM. Substantial underestimation of the need for
25 outpatient services for TIA and minor stroke. *Age Ageing* 2007; 36(6):676-
26 680.
27
- 28 (7) Hart CL, Hole DJ, Smith GD. The relation between questions indicating
29 transient ischaemic attack and stroke in 20 years of follow up in men and
30 women in the Renfrew/Paisley Study. *J Epidemiol Community Health* 2001;
31 55(9):653-656.
32
- 33 (8) Mant J, Wade DT, Winner S. Health care needs assessment: stroke. In:
34 Stevens A, Raftery J, Mant J, Simpson S, editors. Health care needs
35 assessment: the epidemiologically based needs assessment reviews. 2nd ed.
36 Oxford: Radcliffe Medical Press; 2004. 141-244.
37
- 38 (9) Orlandi G, Gelli A, Fanucchi S, Tognoni G, Acerbi G, Murri L. Prevalence of
39 stroke and transient ischaemic attack in the elderly population of an Italian
40 rural community. *Eur J Epidemiol* 2003; 18(9):879-882.
41
- 42 (10) Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE et al.
43 Population-based study of event-rate, incidence, case fatality, and mortality for
44 all acute vascular events in all arterial territories (Oxford Vascular Study).
45 *Lancet* 2005; 366(9499):1773-1783.
46
- 47 (11) Bos MJ, van Rijn MJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM.
48 Incidence and prognosis of transient neurological attacks. *JAMA* 2007;
49 298(24):2877-2885.
50
- 51 (12) Mules J, Henderson M, Kuller L. A population survey of symptoms suggestive
52 of transient ischemic attacks. *Stroke* 1971; 2(2):114-127.
53
54
55
56
57
58
59
60

- 1
2
3 (13) Toole JF, Lefkowitz DS, Chambless LE, Wijnberg L, Paton CC, Heiss G.
4 Self-reported transient ischemic attack and stroke symptoms: methods and
5 baseline prevalence. The ARIC Study, 1987-1989. *Am J Epidemiol* 1996;
6 144(9):849-856.
7
8 (14) Wilkinson WE, Heyman A, Burch JG, Ostfeld A, Labarthe DR, Leviton A et
9 al. Use of a self-administered questionnaire for detection of transient cerebral
10 ischemic attacks: I. Survey of elderly persons living in retirement facilities.
11 *Ann Neurol* 1979; 6(1):40-46.
12
13 (15) Bots ML, van der Wilk EC, Koudstaal PJ, Hofman A, Grobbee DE. Transient
14 neurological attacks in the general population. Prevalence, risk factors, and
15 clinical relevance. *Stroke* 1997; 28(4):768-773.
16
17 (16) Howard VJ, McClure LA, Meschia JF, Pulley L, Orr SC, Friday GH. High
18 prevalence of stroke symptoms among persons without a diagnosis of stroke or
19 transient ischemic attack in a general population: the REasons for Geographic
20 And Racial Differences in Stroke (REGARDS) study. *Arch Intern Med* 2006;
21 166(18):1952-1958.
22
23 (17) van Wijk I, Kappelle LJ, van GJ, Koudstaal PJ, Franke CL, Vermeulen M et
24 al. Long-term survival and vascular event risk after transient ischaemic attack
25 or minor ischaemic stroke: a cohort study. *Lancet* 2005; 365(9477):2098-2104.
26
27 (18) Clark TG, Murphy MF, Rothwell PM. Long term risks of stroke, myocardial
28 infarction, and vascular death in "low risk" patients with a non-recent transient
29 ischaemic attack. *J Neurol Neurosurg Psychiatry* 2003; 74(5):577-580.
30
31 (19) Brayne C, McCracken C, Matthews FE. Cohort profile: the Medical Research
32 Council Cognitive Function and Ageing Study (CFAS). *Int J Epidemiol* 2006;
33 35(5):1140-1145.
34
35 (20) Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical
36 method for grading the cognitive state of patients for the clinician. *J Psychiatr*
37 *Res* 1975; 12(3):189-198.
38
39 (21) Copeland JR, Dewey ME, Griffiths-Jones HM. A computerized psychiatric
40 diagnostic system and case nomenclature for elderly subjects: GMS and
41 AGE-CAT. *Psychol Med* 1986; 16(1):89-99.
42
43 (22) Lasserson DS. Initial management of suspected transient cerebral ischaemia
44 and stroke in primary care: implications of recent research. *Postgrad Med J*
45 2009; 85(1006):422-427.
46
47 (23) Jones WJ, Williams LS, Meschia JF. Validating the Questionnaire for
48 Verifying Stroke-Free Status (QVSFS) by neurological history and
49 examination. *Stroke* 2001; 32(10):2232-2236.
50
51 (24) Wilson A, Potter J, Taub N, Moore A, Robinson T. The effectiveness of a
52 modified version of the Wilkinson questionnaire in screening for TIA and
53 minor stroke in the United Kingdom. *Age Ageing* 2005; 34(1):30-35.
54
55
56
57
58
59
60

- 1
2
3 (25) Murray S, Bashir K, Lees KR, Muir K, MacAlpine C, Roberts M et al.
4 Epidemiological aspects of referral to TIA clinics in Glasgow. *Scott Med J*
5 2007; 52(1):4-8.
6
7 (26) Martin PJ, Young G, Enevoldson TP, Humphrey PR. Overdiagnosis of TIA
8 and minor stroke: experience at a regional neurovascular clinic. *QJM* 1997;
9 90(12):759-763.
10
11 (27) Giles MF, Rothwell PM. Substantial underestimation of the need for
12 outpatient services for TIA and minor stroke. *Age Ageing* 2007; 36(6):676-
13 680.
14
15 (28) Boysen G, Jensen G, Schnohr P. Frequency of focal cerebral transient
16 ischemic attacks during a 12 month period. The Copenhagen city heart study.
17 *Stroke* 1979; 10(5):533-534.
18
19 (29) Johnson SE, Skre H. Transient cerebral ischemic attacks in the young and
20 middle aged. A population study. *Stroke* 1986; 17(4):662-666.
21
22 (30) Amort M, Fluri F, Schafer J, Weisskopf F, Katan M, Burow A et al. Transient
23 ischemic attack versus transient ischemic attack mimics: frequency, clinical
24 characteristics and outcome. *Cerebrovasc Dis* 2011; 32(1):57-64.
25
26 (31) Dawson J, Lamb KE, Quinn TJ, Lees KR, Horvers M, Verrijth MJ et al. A
27 recognition tool for transient ischaemic attack. *QJM* 2009; 102(1):43-49.
28
29 (32) De Haan EH, Nys GM, van Zandvoort MJ. Cognitive function following
30 stroke and vascular cognitive impairment. *Curr Opin Neurol* 2006; 19(6):559-
31 564.
32
33 (33) Selnes OA, Vinters HV. Vascular cognitive impairment. *Nat Clin Pract*
34 *Neurol* 2006; 2(10):538-547.
35
36 (34) Dennis MS, Bamford JM, Sandercock PA, Warlow CP. Incidence of transient
37 ischemic attacks in Oxfordshire, England. *Stroke* 1989; 20(3):333-339.
38
39 (35) Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM et al.
40 Change in stroke incidence, mortality, case-fatality, severity, and risk factors
41 in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). *Lancet* 2004;
42 363(9425):1925-1933.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Demographics of Participants in the Cognitive Function and Aging Study (CFAS)
by sex, age, social class and comorbidity (Data are count (%))

	All (n=11903)		Males (n=4689)		Females (n=7214)	
	N	%*	N	%*	N	%*
Age						
65-74	5980	58.8	2635	64.5	3345	55.0
75-84	4624	32.1	1716	29.6	2908	33.8
85+	1299	9.1	338	5.9	961	11.2
Social Class						
I	558	4.8	225	4.8	333	4.8
II	2988	26.1	1213	26.3	1775	25.9
IIIa	1337	11.6	456	9.9	881	12.8
IIIb	4295	37.7	1865	40.8	2430	35.5
IV	1727	14.9	650	13.9	1077	15.7
V	561	4.9	196	4.3	365	5.3
Comorbidity						
Angina	1923	16.3	878	15.3	1045	11.1
Diabetes	672	5.5	310	6.4	362	4.9
Heart Attack	1139	9.5	632	13.6	507	6.8

*Weighted percentages

Table 2: Distribution and adjusted odds of transient neurological symptoms in those aged 65 or over in the Cognitive Function and Aging Study (CFAS) by sex, social class and comorbidity (Data are count (%))

	Loss of Speech			Weakness			Loss of Sight			At least one symptom		
	N	%*	OR† (95%CI)	N	%*	OR† (95%CI)	N	%*	OR† (95%CI)	N	%*	OR† (95%CI)
Gender												
Male	119	2.5	1.0	257	5.5	1.0	347	7.6	1.0	598	12.8	1.0
Female	152	2.2	0.9(0.7-1.2)	339	4.8	0.9(0.7-1.0)	525	7.6	1.0(0.9-1.2)	858	12.0	1.0 (0.9-1.1)
Age												
65-74	137	2.3	1.0	302	5.1	1.0	480	8.1	1.0	768	12.9	1.0
75-84	104	2.3	0.7(0.7-1.2)	229	5.0	0.9 (0.7-1.1)	327	7.2	0.9(0.7-1.1)	553	12.0	0.9 (0.8-1.0)
85+	30	2.5	0.8(0.5-1.3)	65	5.4	0.9(0.6-1.2)	65	5.4	0.6(0.5-0.8)	134	10.4	0.7 (0.6-0.9)
Social Class												
Non-manual	96	5.8	1.0	63	11.0	1.0	295	17.9	1.0	497	10.2	1.0
Manual	164	7.2	1.1 (0.9-1.5)	390	17.8	1.4 (1.2-1.7)	556	25.7	1.4(1.2-1.6)	920	14.1	1.4 (1.2-1.6)
Comorbidity												

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Angina (n=1538)	64	4.3	1.5(1.0-2.2)	176	11.7	2.5(2.0-3.2)	160	10.6	1.3(1.0-1.6)	312	20.7	1.7(1.4-1.9)
Diabetes (n=672)	28	4.0	1.4(0.9-2.2)	40	6.1	1.0(0.7-1.4)	66	10.1	1.3(0.9-1.7)	102	15.2	1.1(0.9-1.4)
Heart Attack (n=1139)	52	4.7	1.8(1.2-2.7)	131	10.5	1.4(1.2-1.9)	119	11.5	1.4(1.1-1.8)	233	12.4	1.4(1.2-1.8)

* Weighted percentages

† Adjusted for age, sex, social class, cognition and cardiovascular comorbidities

‡ Reference non-manual (I,II, IIIa) compared to manual social class (IIIb,IV,V)

156 participants had missing data on the speech questionnaire, 155 on the weakness and 154 on the sight question

Table 3: Two year incidence of transient neurological symptoms in CFAS in those without stroke at baseline at two yr Screening Assessment, N at 2yrs= 6748 (Data are N (%))

Transient Neurological Symptom	Age							
	All		65-74		75-84		85+	
	N=3657		N=2618		N=2618		N=473	
	N	%*	N	%*	N	%*	N	%*
Loss of Speech	149	2.1	55	1.5	84	3.3	10	2.0
Weakness	239	3.7	117	3.4	106	4.1	16	3.4
Loss of Sight	410	6.3	214	6.3	170	6.6	26	4.5
At least one	675	9.8	327	9.3	304	11.6	44	7.8

*Weighted percentage

98 participants had missing data on the speech questionnaire, 97 on the weakness and 105 on the sight question

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 4: Epidemiological studies of self-reported prevalence of sudden neurological symptoms of weakness of limbs, loss of sight and loss of speech

Table 4a: Frequencies of self-reported sudden weakness of limbs across population studies

Study	Age Range	Date	Population	N	Question	How	Frequencies
Renfrew/ Paisley <i>Hart et al. (2001)</i> ¹	45-64	1972-1976	General population study residents Renfrew&Paisley, Scotland Excluded those with stroke	1511 3	Have you ever without warning suddenly lost the power of an arm?	Questionnaire checked when attended a clinic	344 (2.3%)
Renfrew/ Paisley <i>Hart et al. (2001)</i> ¹	45-64	1972-1976	General population study residents Renfrew&Paisley, Scotland Excluded those with stroke	1511 3	Have you ever without warning suddenly lost the power of a leg?	Questionnaire checked when attended a clinic	363 (2.4%)
Atherosclerosis Risk in Communities (ARIC) Cohort <i>Toole et al (1996)</i> ²	45-64	1987-1989	Four centres in US adults residents	12,205	Have you ever had sudden painless weakness on one side of your body?	Administered by researcher – questions read aloud	283 (2.3%)
Baltimore population study <i>Mules et al (1971)</i> ³	>40	1954-1967	Population samples – two in US	9937	Paralysis within 2 years prior to interview	Interview by trained interviewer	48(0.7%)
Reasons for geographic and racial differences in Stroke (REGARDS) <i>Howard et al (2006)</i> ⁴	> 45 (mean 65)	2003	Community dwelling individuals in US. Those with stroke and TIA excluded	1846 2	Have you ever had sudden painless weakness on one side of the body?	QVSFS questionnaire – telephone and in person	1065 (5.8%)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49	Survey of Elderly Persons Living in Retirement Facilities <i>Wilkinson et al (1979)</i> ⁵	>60	Publishe d 1979	Elderly living in retirement facilities in 8 cities in the US	7281	During last 12 months any sudden occurrence of transient episode of weakness or paralysis of limbs <i>which subsequently cleared up completely</i>	Self- administered questionnaire	197 (2.7%)
---	--	-----	--------------------	---	------	--	--	------------

Table 4b: Frequencies of self-reported sudden speech impairment across population studies

Study	Age Range	Date	Population	N	Question	How	Frequencies
Renfrew/ Paisley <i>Hart et al. (2001)</i> ¹	45-64	1972-1976	General population study residents Renfrew&Paisley, Scotland Excluded those with stroke	15113	Have you ever without warning suddenly been unable to speak properly?	Questionnaire checked when attended a clinic	270 (1.8%)
Atherosclerosis Risk in Communities (ARIC) Cohort <i>Toole et al (1996)</i> ²	45-64	1987-1989	Four centres in US adults residents	12,205	Have you ever had sudden episode of “speech dysfunction”?	Administered by researcher – questions read aloud	313 (2.6%)
Reasons for geographic and racial differences in Stroke (REGARDS) <i>Howard et al (2006)</i> ⁴	> 45 (mean 65)	2003	Community dwelling individuals in US. Those with stroke and TIA excluded	18462	Have you ever had sudden loss of ability to express self verbally (or in writing)?	QVSFS questionnaire – telephone and in person	698 (3.8%)
Survey of Elderly Persons Living in Retirement Facilities <i>Wilkinson et al (1979)</i> ⁵	>60	Published 1979	Elderly living in retirement facilities in 8 cities in the US	7281	During last 12 months experienced any sudden loss of speech or changes in speech <i>which subsequently cleared up completely?</i>	Self-administered questionnaire	149 (2.0%)

Table 4c: Frequencies of self-reported sudden visual impairment across population studies

Study	Age Range	Date	Population	N	Question	How	Frequencies
Atherosclerosis Risk in Communities (ARIC) Cohort <i>Toole et al (1996)</i> ²	45-64	1987-1989	Four centres in US adults residents	12,205	Have you ever had sudden “visual impairment”?	Administered by researcher – questions read aloud	313 (2.6%)
Reasons for geographic and racial differences in Stroke (REGARDS) <i>Howard et al (2006)</i> ⁴	> 45 (mean 65)	2003	Community dwelling individuals in US. Those with stroke and TIA excluded	18462	Have you ever had sudden painless loss of vision in one or both eyes?	QVSFS questionnaire – telephone and in person	698 (3.8%)
Baltimore population study <i>Mules et al (1971)</i> ³	>40	1954-1967	Population samples – two in US	9937	Loss of vision within 2 years prior to interview	Interview by trained interviewer	129 (2.0%)
Survey of Elderly Persons Living in Retirement Facilities <i>Wilkinson et al (1979)</i> ⁵	>60	Published 1979	Elderly living in retirement facilities in 8 cities in the US	7281	During last 12 months experienced sudden loss of eyesight <i>which subsequently cleared up completely?</i>	Self-administered questionnaire	149 (2.0%)

- 1
2
3
4
5
6
7 (1) Hart CL, Hole DJ, Smith GD. The relation between questions indicating transient ischaemic attack and stroke in 20 years of follow up in
8 men and women in the Renfrew/Paisley Study. *J Epidemiol Community Health* 2001; 55(9):653-656.
9
- 10
11 (2) Toole JF, Lefkowitz DS, Chambless LE, Wijnberg L, Paton CC, Heiss G. Self-reported transient ischemic attack and stroke symptoms:
12 methods and baseline prevalence. The ARIC Study, 1987-1989. *Am J Epidemiol* 1996; 144(9):849-856.
13
14
- 15
16 (3) Mules J, Henderson M, Kuller L. A population survey of symptoms suggestive of transient ischemic attacks. *Stroke* 1971; 2(2):114-127.
17
18
- 19
20 (4) Howard VJ, McClure LA, Meschia JF, Pulley L, Orr SC, Friday GH. High prevalence of stroke symptoms among persons without a
21 diagnosis of stroke or transient ischemic attack in a general population: the REasons for Geographic And Racial Differences in Stroke
22 (REGARDS) study. *Arch Intern Med* 2006; 166(18):1952-1958.
23
24
25
- 26
27 (5) Wilkinson WE, Heyman A, Burch JG, Ostfeld A, Labarthe DR, Leviton A et al. Use of a self-administered questionnaire for detection of
28 transient cerebral ischemic attack
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

Table 2: Distribution and unadjusted and adjusted odds of transient neurological symptoms in those aged 65 or over in the Cognitive Function and Aging Study (CFAS)

(Data are count (%))

	Loss of Speech			Weakness			Loss of Sight			At least one symptom		
	N	%*	OR † (95%CI)	N	%*	OR † (95%CI)	N	%*	OR † (95%CI)	N	%*	OR † (95%CI)
Gender												
Male	119	2.5	1.0	257	5.5	1.0	347	7.6	1.0	598	12.8	1.0
Female	152	2.2	0.9(0.7-1.1)	339	4.8	0.9(0.7-1.0)	525	7.6	0.9(0.9-1.1)	858	12.0	0.9(0.7-1.1)
			0.9 (0.7-1.2)			0.9(0.7-1.0)			1.0(0.9-1.2)			1.0 (0.9-1.1)
Age												
65-74	137	2.3	1.0	302	5.1	1.0	480	8.1	1.0	768	12.9	1.0
75-84	104	2.3	1.0(0.8-1.3)	229	5.0	0.9(0.8-1.2)	327	7.2	0.9(0.7-1.0)	553	12.0	0.9(0.8-1.0)
			0.7(0.7-1.2)			0.9(0.7-1.1)			0.9(0.7-1.1)			0.9 (0.8-1.0)
85+	30	2.5	1.1(0.7-1.6)	65	5.4	1.1(0.8-1.4)	65	5.4	0.6(0.5-0.8)	134	10.4	0.8(0.6-0.9)

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

			0.8(0.5-1.3)			0.9(0.6-1.2)			0.6(0.5-0.8)			0.7 (0.6-0.9)
Social Class												
Non-manual	96	5.8	1.0	63	11.0	1.0	295	17.9	1.0	497	10.2	1.0
Manual	164	7.2	1.3(†9-1.6)	390	17.8	1.6(1.3-1.9)	556	25.7	1.4(1.2-1.7)	920	14.1	1.4(1.3-1.6)
			1.1 (0.9-1.5)			1.4 (1.2-1.7)			1.4(1.2-1.6)			1.4 (1.2-1.6)
Comorbidity												
Angina (n=1538)	64	4.3	2.2(1.7-2.9)	176	11.7	3.1(2.6-3.8)	160	10.6	1.5(1.3-1.9)	312	20.7	2.1(1.8-2.4)
			1.5(1.0-2.2)			2.5(2.0-3.2)			1.3(1.0-1.6)			1.7(1.4-1.9)
Diabetes (n=672)	28	4.0	1.8(1.2-2.8)	40	6.1	1.2(†9-1.7)	66	10.1	1.4(1.0-1.8)	102	15.2	1.3(1.0-1.6)
			1.4(0.9-2.2)			1.0(0.7-1.4)			1.3(0.9-1.7)			1.1(0.9-1.4)
Heart Attack (n=1139)	52	4.7	2.3(1.7-3.2)	131	10.5	2.5(2.0-3.1)	119	11.5	1.7(1.4-2.1)	233	12.4	1.9(1.7-3.2)
			1.8(1.2-2.7)			1.4(1.2-1.9)			1.4(1.1-1.8)			1.4(1.2-1.8)

* Weighted percentages

†Adjusted for age, sex, social class, cognition and cardiovascular comorbidities

‡ Reference non-manual (I,II, IIIa) compared to manual social class (IIIb,IV,V)

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

156 participants had missing data on the speech questionnaire, 155 on the weakness and 154 on the sight question

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

For peer review only

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

COHORT PROFILE

Cohort Profile: The Medical Research Council Cognitive Function and Ageing Study (CFAS)[†]

Carol Brayne,^{1*} Cherie McCracken² and Fiona E Matthews³

Origin of the study

Global ageing is a recent phenomenon. Its potential impact on social and economic aspects of more affluent countries highlighted ageing as a sufficiently important issue towards which to direct resources. Discussion between the Department of Health, Medical Research Council, and experts from the scientific and medical communities resulted in the decision that brain changes, most particularly cognitive decline, dementia, and their relation to disability were key topics requiring investigation at the population level. This prompted a decision to invest in research into this area and a working group was convened, which included those with epidemiological and biostatistical expertise relevant to such investigation. Out of this working group a successful bid for the study now known as the MRC Cognitive Function and Ageing Study emerged.

Study design

The study is a six-centre multidisciplinary multiphased longitudinal design (see map, Figure 1). There are five identical sites and one with a different sampling and interview structure. This centre (Liverpool) was already funded at the time of the discussions noted above and thus started earlier than the other five centres.¹ The other five centres (Cambridgeshire, Gwynedd, Newcastle, Nottingham, and Oxford) were able to follow a standardized design and are referred to as the five identical sites. Their basic structure was a two-phase design with a screening interview followed by an assessment interview shortly afterwards, with a repeat at 2 years. The fieldwork began in 1991.² There are many additional features, which are more fully described on the website (see below).

The aims of the study

The aims of the study have evolved over its existence and cover a wide range including descriptive

epidemiology, neuropathology, policy, molecular epidemiology, and ethics.

The main descriptive epidemiological aims include (i) the estimation of the prevalence and incidence of cognitive decline and dementia, and geographical variation in those rates; (ii) the determination of the natural history of dementia, in particular the rate of progression of cognitive decline including the distribution of the interval between the identification of cognitive impairment and death, and (iii) the identification of factors associated with differing rates of cognitive decline and with the risk of dementia.

The principal neuropathological aim was to determine the contribution of different underlying pathologies to the rates of dementia and the geographic variation in these rates and to the burden of disability. Additional aims included to: (i) determine the prevalence and severity of pathological lesions in the brain of an unselected cohort of older people with and without cognitive impairment; (ii) determine the frequency of specific pathological diagnoses in people with cognitive impairment, and (iii) correlate severity of specific pathologies with patterns of cognition, function, and behaviour in life independently of clinical and pathological diagnostic categories.

The core aim related to policy was the evaluation of the degree of disability associated with cognitive decline and impairment, and the service needs this disability generates. These needs were to be compared with the needs generated by physical impairment. The study also sought to form the basis for longer-term studies of trends over time and by birth cohort of the prevalence and incidence of cognitive decline. In addition to these aims the breadth of the data collected has allowed the study to incorporate the investigation of expectation of life in various states of health, depression, and depressive symptomatology in the older population.

The DNA resource has been incorporated in a later phase of the study. The main molecular epidemiological aim has been to support genetics studies that have sought genes associated with all dementia, Alzheimer's disease, mixed and vascular dementia, cognitive impairment and decline.

A later aim of the study was to explore the ethical and legal aspects of brain donation within a population-based sample given changing perception surrounding organ donation.

The study also aimed to act as a core resource and provide a framework to support specific sub-studies in lone or joint centres. The Resource Implication Study^{3–9} utilized this framework to achieve the core policy aim (see above). Other

¹ Department of Public Health and Primary Care, Institute of Public Health, Cambridge University, Forvie Site, Robinson Way, Cambridge CB2 2SR, UK.

² Department of Psychiatry, University of Liverpool University, Clinical Dept Duncan Building Liverpool L69 3BX, UK.

³ MRC Biostatistics Unit, Institute of Public Health, Forvie Site, Robinson Way, Cambridge CB2 2SR, UK.

* Corresponding author. E-mail: Carol.Brayne@medschl.cam.ac.uk

[†] A full list of the study investigators and contributors is available on the website.



Figure 1 Map of Great Britain showing CFAS centres

sub-studies include the study of Healthy Ageing^{10–15} and the Network Study. This framework also extends to wider collaborations with CFAS centres contributing to European wide initiatives such as EURODEM¹⁶ and EURODEP.¹⁷

What does it cover?

Because the main study is focused on cognition and dementia it has collected the necessary dimensions of physical and mental health to arrive at a study diagnosis of dementia. It now has four major themes: (i) dementia (covering all aspects including cognition), (ii) depression, (iii) disability and healthy life expectancy, and (iv) health policy and health. In addition it has particular strengths in that it is one of the very few truly population based programmes with a donation programme—individuals in the study have indicated whether they wish to contribute to brain research through the donation of their brain after death (declaration of intention to donate).

Who is in the sample?

The first aim of the study was to estimate age-specific rates of prevalence of cognitive impairment and dementia among those aged 65 and over. The population is thus all

those aged 65 years and over on the index date for centre (1990, 1991), living within a specified geographical location. Background information on the demographics of the populations sampled was collected from the Office of Population Census and Surveys (OPCS), 1990–91 census now Office of National Statistics (ONS), to relate to regional and national data.

Family Health Service Authority (FHSA) lists were used as the sampling frame. The frame would be incomplete if eligible members of the population were not registered with a GP. However individuals in long-stay hospitals remain registered with their GP 2 years after institutionalization so sampling from FHSA lists ensured their inclusion. Each centre looked into the practices of long-stay hospitals in their area to confirm this. The FHSA list of individuals was used for sampling on a geographical basis. Each centre defined this area, and the study population was drawn from all those who were resident within it. Problems of inaccuracy, patients who died or moved away but were still on the FHSA list, were resolved by asking GP surgeries to check the lists. On this basis, a sample of sufficient size to yield 2500 interviews of individuals aged 65 years and over, stratified by age (equal numbers aged 65–74 and 75 plus) was chosen from the FHSA lists for each selected area (in Liverpool this was 5000 interviews stratified by sex and 5 year age band). The population is flagged at ONS for mortality and the database is updated continuously.

The follow-up has been determined by funding and the design of associated bolt-on studies. The main follow-up waves for the identical sites are captured in the audit trail shown in Figure 2, which shows the numbers for the main screen, assessment, 1 year follow-up and 2 year rescreen, new selection for assessment and further 1 year follow-up, 6 year follow-up of the assessed (with venepuncture), 8 year follow-up of those with intentions to donate, and 10 year follow-up of the total sample. In addition to this the main associated studies are the Resource Implication Study (4 centres—Cambridgeshire, Newcastle, Nottingham, Oxford), which followed those who provided care to the physically and cognitively frail at baseline, the ESRC funded Healthy Ageing Project, which interviewed in detail those who were not selected into the Resource Implication Study in Nottingham and Cambridgeshire, the Network Study conducted in Gwynedd and Liverpool to examine individuals' social networks, an embedded case-control study at 2 year incidence stage (Cambridgeshire), and the ongoing brain donation programme in all centres. This programme, in combination with the bloods taken at year 6 form the major components of the Biological Resource of the study.

Who is not in the sample?

Comprehensive analyses of those who were lost to follow-up have been conducted for all stages of the study. At baseline 19% of potential respondents refused, 6% had died, and 1% had moved out of the area. Similar percentages were found for all waves of the study. Individuals who had moved or refused had higher mortality than responders.¹⁸ CFAS has used this attrition for a detailed investigation of attrition effects in both short and longer time intervals.^{18,19}




Figure 2 Time frame of CFAS interviews (identical centres)

How, when, and which interviews were conducted?

All interviews were conducted in the respondent's place of residence, using portable computers with customized software. If the interviewer felt that the respondent was frail and tiring, or becoming agitated, the short 'priority mode' set of questions could be invoked manually. Screening interviews were undertaken by lay interviewers, recruited for the purpose and trained by both the local and national coordinator. Reliability checks were made by both the local and the national coordinator. Proxy screening interviews were conducted where an interview was not possible with the named participant, owing to, for example, extreme confusion or frailty. If after four attempts to contact, an interview was not arranged, the approach was abandoned. The screening of the entire sample took 2 years to complete.

The assessment (designed to be conducted 1 month after the screening interview) and annual (designed to be conducted

1 year after the screening interview) interviews were also undertaken using customized portable computers. These interviews were carried out by interviewers from professions allied to medicine, who had not undertaken the screening interview, also recruited and trained for the purpose. Interviewers did not know the outcome of the first interview. The interviews lasted from 45 to 90 min, again with a 'priority mode' route. The annual interview consisted of a combined screen and assessment, where information on changes since last interview was recorded. At the assessment and biannual follow-up interview permission was sought to approach and interview a relative or carer to ask for an objective account of the respondent's health and abilities.

Six years after the initial screening interview, all respondents in the assessed groups were interviewed using the combined screen and assessment interview and at the end of that interview signed permission was requested to take a sample of blood or saliva. Permission was also sought to access GP and hospital notes. At 8 years only those who had indicated an

intention to donate brain tissue were re-interviewed with the combined screen and assessment interview.

At 10 years all survivors from the responding group of the complete study were recontacted for interview and if they agreed were interviewed using the combined screen and assessment interview.

What is collected at different interviews?

The screening interview contains questions on residence, marital status, education and occupation, living circumstances, contact with friends and family, health and social care contact, self-reported physical health, instrumental activities of daily living and activities of daily living, cognitive measures (Mini Mental State Examination with augmentation), and medication.

The assessment interview is mainly the Geriatric Mental State Examination (GMS) adapted for CFAS.²⁰ This is a structured psychiatric interview, which collects sufficient information for algorithmic 'diagnosis' in the major psychiatric disorders of old age (dementia, depression, anxiety, and psychosis). This has been validated against clinical diagnosis and the instrument has been widely used in Europe and now forms part of the 10/66 international instrument. This interview has been augmented with questions from the CAMDEX (Cambridge Examination for Mental Disorders in the Elderly) including CAMCOG,²¹ the longer neuropsychological assessment. The relative or carer interview is mainly the History and Aetiological Schedule, the informant interview that accompanies the GMS.

The combined screen and assessment interview merges the two interviews but compresses some aspects of data collection. Complete versions of all the interviews including the interview questions and responses are available on the website.

The neuropathological assessment follows the standardized protocol of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD)²², with the exception that the neuropathologist is blind to the interview data. This covers in a semiquantitative form the main areas required for the assessment of neurodegenerative and cerebrovascular disorders. The forms are available on the website. The main genetic analyses have been on apoE and ACE.

Data collection in Liverpool was broadly similar to the other five sites except that the screening interview consisted of the GMS plus some of the screening interview questions listed above.

What has the study found?

The study has reported on prevalence and incidence of dementia, and lack of variation in these across the five identical sites.^{23–25} It has provided profiles of cognition for MMSE, extended MMSE, and CAMCOG, weighted back to the population.^{26,27} It has reported on risk for incident dementia including apoE and ACE.^{28–30} It has examined the relationship of cognition to mortality.^{18,31} It has reported on the mixed neuropathology found in the brains of the oldest old.³² In addition, the study has reported on a variety of impairments to healthy life in old age and their population burden.^{33–38}

The Resource Implication Study has provided data for examination of carer burden and the costs of care for physically and cognitively frail.^{3–9,39} The data have been used for projection forward, for these vulnerable groups and also for the costs of long-term care. Liverpool has published on the prevalence of dementia, depression, and neurosis, together with incidence of dementia and schizophrenia.^{40–43}

What are the main strengths?

The study is multisite and multidisciplinary. The population is truly representative with high response rates at each stage over diverse sites. Where there is no heterogeneity across sites the study is sufficiently large to provide indicative values for national estimates. The broad scope of measures has allowed the study to contribute to ageing research across a wide range of topics. There are repeat measures on cognition and function, which allows examination of trajectories. There are only two other population-based studies with brain donation in Europe.^{44,45} The study weighted the sample towards the over 75 age group at baseline, which has provided more robust data for the oldest old.

What are the main weaknesses?

It would be desirable to have higher response and lower drop out between waves, but analysis can adjust for loss between interviews. Blood taking and clinical assessment (including imaging) at baseline was not possible because of funding constraints, but venepuncture was included at year 6. The risk measures are self-report, using the available validated measures of the era.

Can I get hold of data?

The study actively encourages collaboration, and there are established mechanisms for approaching us via the themes mentioned above (see What does it cover?). Information is available on the website and also through contact with theme leads.

Where can I find out more?

The study website, www.cfas.ac.uk, configures information under themes, documentation, publications, and data. There is also a list of study contacts.

Acknowledgements

We are grateful to our respondents, their families, and their primary care teams. The study has only been possible because of the dedication of a large number of individuals over the years who are listed on the website. The MRC CFA Study has been supported by major awards from the Medical Research Council and the Department of Health. Thanks are also due to the Biological Resource Advisory Group for overseeing this aspect of study and to Lu Gao for preparation of the manuscript.

References

- 1 Saunders PA, Copeland JR, Dewey ME, Larkin BA, Scott A. Alpha: the Liverpool MRC Study of the incidence of dementia and cognitive decline. *Neuroepidemiology* 1992;**11**(suppl. 1):44–47.
- 2 Chadwick C. The MRC Multicentre Study of Cognitive Function and Ageing: a EURODEM incidence study in progress. *Neuroepidemiology* 1992;**11**(suppl. 1):37–43.
- 3 Buck D, Gregson BA, Bamford CH *et al*. Psychological distress among informal supporters of frail older people at home and in institutions. The Resource Implications Study Group of the MRC Cognitive Function and Ageing Study. *Int J Geriatr Psychiatry* 1997;**12**:737–44.
- 4 McNamee P, Gregson BA, Wright K, Buck D, Bamford CH, Bond J. Estimation of a multiproduct cost function for physically frail older people. *Health Econ* 1998;**7**:701–10.
- 5 McNamee P, Gregson BA, Buck D, Bamford CH, Bond J, Wright K. Costs of formal care for frail older people in England: the resource implications study of the MRC cognitive function and ageing study (RIS MRC CFAS). *Soc Sci Med* 1999;**48**:331–41.
- 6 Bond J, Farrow G, Gregson BA *et al*. Informal caregiving for frail older people at home and in long-term care institutions: who are the key supporters? *Health Soc Care Community* 1999;**7**:434–44.
- 7 Melzer D, McWilliams B, Brayne C, Johnson T, Bond J. Profile of disability in elderly people: estimates from a longitudinal population study. *BMJ* 1999;**318**:1108–11.
- 8 Psychological morbidity among informal caregivers of older people: a 2-year follow-up study. The Resource Implications Study Group of the MRC study of cognitive function and ageing (RIS MRC CFAS). *Psychol Med* 2000;**30**:943–55.
- 9 McNamee P, Bond J, Buck D. Costs of dementia in England and Wales in the 21st century. *Br J Psychiatry* 2001;**179**:261–66.
- 10 Solomou W, Richards MPM, Huppert FA, Brayne C, Morgan K. Divorce, current marital status and well-being in an elderly population. *Int J Law, Policy and the Family* 1998;**12**:321–342.
- 11 Huppert FA, Solomou W, O'Connor S, Morgan K, Sussams P, Brayne C. Aging and lymphocyte subpopulations: whole-blood analysis of immune markers in a large population sample of healthy elderly individuals. *Exp Gerontol* 1998;**33**:593–600.
- 12 Morgan K, Armstrong GK, Huppert FA, Brayne C, Solomou W. Healthy ageing in urban and rural Britain: a comparison of exercise and diet. *Age Ageing* 2000;**29**:341–48.
- 13 Huppert FA, Pinto EM, Morgan K, Brayne C. Survival in a population sample is predicted by proportions of lymphocyte subsets. *Mech Ageing Dev* 2003;**124**:449–51.
- 14 Huppert FA, Pinto E, Morgan K, MRC CFAS, Brayne C. Immune measures which predict 9-year survival in an elderly population sample. *Basic Biology and Clinical Impact of Immunosenescence, Advances in Cell Aging and Gerontology* 2003;**13**:17–28.
- 15 Pinto EM, Huppert FA, Morgan K, Mrc C, Brayne C. Neutrophil counts, monocyte counts and cardiovascular disease in the elderly. *Exp Gerontol* 2004;**39**:615–19.
- 16 Rocca WA, Hofman A, Brayne C *et al*. The prevalence of vascular dementia in Europe: facts and fragments from 1980–1990 studies. EURODEM-Prevalence Research Group. *Ann Neurol* 1991;**30**:817–24.
- 17 Copeland JR, Beekman AT, Braam AW *et al*. Depression among older people in Europe: the EURODEP studies. *World Psychiatry* 2004;**3**:45–49.
- 18 Matthews FE, Chatfield M, Freeman C, McCracken C, Brayne C. Attrition and bias in the MRC cognitive function and ageing study: an epidemiological investigation. *BMC Public Health* 2004;**4**:12.
- 19 Matthews FE, Chatfield M, Brayne C. An investigation of whether factors associated with short-term attrition change or persist over ten years: data from the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). *BMC Public Health* 2006;**6**:185.
- 20 Copeland JR, Dewey ME, Griffiths-Jones HM. A computerized psychiatric diagnostic system and case nomenclature for elderly subjects: GMS and AGE-CAT. *Psychol Med* 1986;**16**:89–99.
- 21 Huppert FA, Brayne C, Gill C, Paykel ES, Beardsall L. CAMCOG—a concise neuropsychological test to assist dementia diagnosis: socio-demographic determinants in an elderly population sample. *Br J Clin Psychol* 1995;**34**:529–41.
- 22 Mirra SS, Heyman A, McKeel D *et al*. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 1991;**41**:479–86.
- 23 Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study. The Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). *Psychol Med* 1998;**28**:319–35.
- 24 Matthews F, Brayne C. The incidence of dementia in England and Wales: findings from the five identical sites of the MRC CFA Study. *PLoS Med* 2005;**2**:e193.
- 25 Matthews FE, Dening T. Prevalence of dementia in institutional care. *Lancet* 2002;**360**:225–26.
- 26 Williams JG, Huppert FA, Matthews FE, Nickson J. Performance and normative values of a concise neuropsychological test (CAMCOG) in an elderly population sample. *Int J Geriatr Psychiatry* 2003;**18**:631–44.
- 27 Huppert FA, Cabelli ST, Matthews FE. Brief cognitive assessment in a UK population sample—distributional properties and the relationship between the MMSE and an extended mental state examination. *BMC Geriatr* 2005;**5**:7.
- 28 Yip AG, Brayne C, Matthews FE. Risk factors for incident dementia in England and Wales: The Medical Research Council Cognitive Function and Ageing Study. A population-based nested case-control study. *Age Ageing* 2006;**35**:154–60.
- 29 Yip AG, Brayne C, Easton D, Rubinsztein DC. An investigation of ACE as a risk factor for dementia and cognitive decline in the general population. *J Med Genet* 2002;**39**:403–06.
- 30 Yip AG, Brayne C, Easton D, Rubinsztein DC. Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population. *J Med Genet* 2002;**39**:639–43.
- 31 Neale R, Brayne C, Johnson AL. Cognition and survival: an exploration in a large multicentre study of the population aged 65 years and over. *Int J Epidemiol* 2001;**30**:1383–88.
- 32 Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). *Lancet* 2001;**357**:169–75.
- 33 Brayne C, Gao L, Matthews F. Challenges in the epidemiological investigation of the relationships between physical activity, obesity, diabetes, dementia and depression. *Neurobiol Aging* 2005;**26**(suppl. 1):6–10.
- 34 Jagger C, Matthews F. Gender differences in life expectancy free of impairment at older ages. *J Women Aging* 2002;**14**:85–97.
- 35 McGee MA, Johnson AL, Kay DW. The description of activities of daily living in five centres in England and Wales. Medical Research Council Cognitive Function and Ageing Study. *Age Ageing* 1998;**27**:605–13.
- 36 Melzer D, McWilliams B, Brayne C, Johnson T, Bond J. Socioeconomic status and the expectation of disability in old age: estimates for England. *J Epidemiol Commun Health* 2000;**54**:286–92.
- 37 Parker CJ, Morgan K, Dewey ME. Physical illness and disability among elderly people in England and Wales: the Medical Research Council Cognitive Function and Ageing Study. The Analysis Group. *J Epidemiol Commun Health* 1997;**51**:494–501.
- 38 Spiers NA, Matthews RJ, Jagger C *et al*. Diseases and impairments as risk factors for onset of disability in the older population in England and

- Wales: findings from the Medical Research Council Cognitive Function and Ageing Study. *J Gerontol A Biol Sci Med Sci* 2005;**60**:248–54.
- ³⁹ Comas-Herrera A, Wittenberg R, Pickard L, Knapp M, MRC-CFAS. Cognitive impairment in older people: its implications for future demand for services and costs. *Mental Health Research Review* 2001;**8**:37–38.
- ⁴⁰ Copeland JR, Chen R, Dewey ME *et al.* Community-based case-control study of depression in older people. Cases and sub-cases from the MRC-ALPHA Study. *Br J Psychiatry* 1999;**175**:340–47.
- ⁴¹ Copeland JR, McCracken CF, Dewey ME *et al.* Undifferentiated dementia, Alzheimer's disease and vascular dementia: age- and gender-related incidence in Liverpool. The MRC-ALPHA Study. *Br J Psychiatry* 1999;**175**:433–38.
- ⁴² Copeland JR, Dewey ME, Scott A *et al.* Schizophrenia and delusional disorder in older age: community prevalence, incidence, comorbidity, and outcome. *Schizophr Bull* 1998;**24**:153–61.
- ⁴³ Saunders PA, Copeland JR, Dewey ME *et al.* The prevalence of dementia, depression and neurosis in later life: the Liverpool MRC-ALPHA Study. *Int J Epidemiol* 1993;**22**:838–47.
- ⁴⁴ Polvikoski T, Sulkava R, Myllykangas L *et al.* Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study. *Neurology* 2001;**56**:1690–96.
- ⁴⁵ Xuereb JH, Brayne C, Dufouil C *et al.* Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. *Ann N Y Acad Sci* 2000;**903**:490–96.

For peer review only

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

- see below **

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
		(b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
		(c) Explain how missing data were addressed
		(d) If applicable, explain how loss to follow-up was addressed
		(e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
		(b) Indicate number of participants with missing data for each variable of interest
		(c) Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Report numbers of outcome events or summary measures over time
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
		(b) Report category boundaries when continuous variables were categorized

		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

STROBE checklist

Item	Reported on page
1(a)	1
1(b)	2
2	3,4
3	4
4	4,5
5	4-7
6 (a)	4,5
7	6
8	5,6
9	6
10	Described elsewhere - see references 1 and 2
11	6
12 (a)	6,7
12 (b)	6,7
12 (c)	6,7
12 (d)	6,7 – described elsewhere see references 1 and 2
12 (e)	N/A
13 (a)	7
13 (b)	7
13(c)	Described elsewhere – see reference 1
14 (a)	7
14(b)	see tables
14 (c)	6

1	15 cohort study	N/A
2	16(a)	see additional table
3	16(b)	N/A
4	16 (c)	N/A
5	17	7/8
6	18	7/8
7	19	11
8	20	9/10
9	21	9/10
10	22	13

Reference 1:

Brayne C, McCracken C, Matthews FE. Cohort profile: the Medical Research Council Cognitive Function and Ageing Study (CFAS). *Int J Epidemiol* 2006; 35(5):1140-1145.

Matthews FE, Chatfield M, Freeman C, McCracken C, Brayne C, MRC CFAS (2004), "Attrition and bias in the MRC cognitive function and ageing study: an epidemiological investigation." *BMC Public Health* 4:12

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting <http://www.adobe.com/products/acrobat/readstep2.html>.

For more assistance with Adobe Reader visit <http://www.adobe.com/support/products/acrreader.html>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.



**Transient neurological symptoms in the older population:
Report of a prospective cohort study - the Medical Research
Council Cognitive Function and Ageing (CFAS) Study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003195.R1
Article Type:	Research
Date Submitted by the Author:	11-Jun-2013
Complete List of Authors:	Mavaddat, Nahal; University of Cambridge, Department of Public Health and Primary Care Savva, George; University of East Anglia, School of Nursing Sciences Lasserson, Daniel; University of Oxford, Primary Care Health Sciences giles, matthew; John Radcliffe Hospital, NIHR Biomedical Research Unit Brayne, Carol; University of Cambridge, Institute of Public Health Mant, Jonathan; University of Cambridge, General Practice and Primary Care Research Unit
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Cardiovascular medicine, Epidemiology
Keywords:	Stroke < NEUROLOGY, EPIDEMIOLOGY, Stroke medicine < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts

Only

1
2
3
4 **Transient neurological symptoms in the older population: Report of a**
5 **prospective cohort study - the Medical Research Council Cognitive**
6 **Function and Ageing Study (CFAS)**
7
8
9

10
11 **Nahal Mavaddat, George M Savva, Daniel Lasserson, Matthew Giles,**
12 **Carol Brayne, Jonathan Mant**
13

14
15
16
17 **Department of Public Health and Primary Care, University of Cambridge,**
18 **Strangeways Laboratory, Worts Causeway, Cambridge, UK CB1 8RN**
19 **Nahal Mavaddat clinical lecturer Jonathan Mant professor**
20

21
22 **School of Nursing Sciences, University of East Anglia, Norwich Research**
23 **Park, Norwich, UK, NR4 7TJ. George Savva senior lecturer**
24

25
26 **Department of Primary Care Health Sciences, University of Oxford,**
27 **Oxford, U.K. New Radcliffe House, 2nd floor, Walton Street, Jericho, UK**
28 **OX2 6NW Daniel Lasserson clinical lecturer**
29

30
31 **Stroke Prevention Research Unit, NIHR Biomedical Research Centre,**
32 **Oxford University, Department of Clinical Neurology, John Radcliffe**
33 **Hospital, Oxford, UK OX3 9DU Matthew Giles consultant physician**
34

35
36 **Department of Public Health and Primary Care, University of Cambridge,**
37 **Institute of Public Health, Forvie Site, Robinson Way Causeway,**
38 **Cambridge, UK CB2 0SR Carol Brayne professor**
39

40
41
42 **Correspondence to: Nahal Mavaddat nm212@medschl.cam.ac.uk**
43
44

45
46
47 The Corresponding Author has the right to grant on behalf of all authors and does grant on
48 behalf of all authors, an exclusive licence (or non exclusive for government employees) on a
49 worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be
50 published in BMJ editions and any other BMJ PGL products and sublicences such use and
51 exploit all subsidiary rights, as set out in our licence.
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article Summary

Article Focus:

- Prompt initiation of secondary prevention following TIA is associated with up to 80% reduction in risk of subsequent stroke.
- Many people presenting to specialist TIA clinics with transient neurological symptoms do not have TIA.
- The prevalence and incidence of transient neurological symptoms (as opposed to TIA) in older age groups is unknown.

Key Messages:

- In a large multi-centred community based study representative of the older population in the UK, we found a high prevalence and incidence of transient neurological symptoms, significantly greater than that of TIAs in hospital and population-based studies.

The high rates of transient neurological symptoms in the community in the older population should be considered when planning TIA services.

Strengths and Limitations of this study:

- Strengths - Previous studies of incidence and prevalence of transient neurological symptoms have mostly been conducted in populations not representative of older age groups where TIA is most common and few have been undertaken in UK populations.
- Limitations - The incidence of transient neurological symptoms in the study was determined in people without severe cognitive impairment, and may be an underestimate since cognitive impairment can be a manifestation of vascular disease.

1
2
3 The wording of questions to identify transient neurological symptoms may have
4
5 picked up some people who had symptoms lasting more than 24 hours.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT

Objective: Transient ischaemic attack (TIA) is a recognised risk factor for stroke in the older population requiring timely assessment and treatment by a specialist. The need for such TIA services is driven by the epidemiology of transient neurological symptoms, which may not be caused by TIA. We report prevalence and incidence of transient neurological symptoms in a large UK cohort study of older people. **Design** Longitudinal cohort study **Setting and Participants:** The MRC Cognitive Function and Aging Study (CFAS) is a population representative study derived from random samples of people in their 65th year. Interview at baseline included questions about stroke and three transient neurological symptoms, repeated in a sub-sample after two years. Patients were flagged for mortality. **Main Outcome Measures** Prevalence and two year incidence of transient neurological symptoms. **Results** In 11,903 participants without a history of stroke, 271 (2.3%) reported transient problems with speech, 872 (7.6%) with sight, and 596 (5.1%) weakness in a limb, with 1456 (12.7%) reporting at least one symptom. Of those re-interviewed (n=6748), 675 (9.8%) reported at least one symptom over two years. **Conclusions** Lifetime prevalence and incidence of transient neurological symptoms in people 65 and over is high and is substantially greater than the incidence of TIA in hospital and population-based studies. These high rates of transient neurological symptoms in the community in the older population should be considered when planning TIA services.

INTRODUCTION

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Transient ischaemic attack (TIA) is an established and powerful risk factor for stroke. 8% of patients who have a TIA suffer a stroke within 7 days, many within 48 hours.^{1,2} Immediate specialist assessment and treatment is associated with substantial reductions in this early risk of stroke,³ and is recommended for people with suspected TIA.⁴

As awareness grows of the urgency of early management of TIA amongst both primary care practitioners and the general public,⁵ more patients with symptoms suggestive of a TIA are likely to present to primary and secondary care services. Need for specialist services will be driven by incidence of symptoms that might represent TIA (i.e. transient neurological symptoms) rather than the epidemiology of TIA *per se*. Currently about 48,000 probable or definite TIAs (transient neurological symptoms lasting less than 24 hours of likely vascular aetiology), and 43,000 minor strokes (stroke events causing minimal or no neurological deficits) are managed as outpatients every year in England, but it is not clear to what extent this might be the tip of the iceberg.⁶ Data are available worldwide on the prevalence and incidence of TIA.⁷⁻¹¹ The epidemiology in the community of transient neurological symptoms (i.e. neurological symptoms of sudden onset of which TIA is a subset), is however less well defined. Previous studies of incidence and prevalence of transient neurological symptoms, have mostly been conducted in populations not representative of older age groups where TIA is most common.^{7;11-16} Very few have been undertaken in UK populations. While incidence of transient neurological symptoms will drive need for specialist TIA services, prevalence of transient neurological symptoms in the community is also important. TIA is associated with a long term increase in risk of stroke,^{17,18} so there may be value in diagnosing 'old' events that have not presented to medical services in order to target

1
2
3 secondary prevention. Hence the need to know both the incidence and prevalence of transient
4
5 neurological symptoms in the community.
6
7
8

9
10 This study reports prevalence and incidence of three common transient neurological
11 symptoms (limb weakness, loss of speech and disturbance of vision) in a population based
12 multi-centred cohort study in the UK (England and Wales) in those aged 65 and over, the
13 Medical Research Council Cognitive Function and Ageing Study (CFAS).¹⁹
14
15
16
17
18

19 20 21 **METHODS**

22
23 The Medical Research Council CFAS is a population representative study of individuals aged
24 65 years and over. The study began in 1991 and was designed to determine the incidence of
25 dementia in the older population. It has six centres across England and Wales chosen to
26 represent the national variation of urban-rural mix, socio-economic deprivation and rates of
27 chronic disease.¹⁹ Five of these with identical study designs (Oxford, Nottingham,
28 Cambridgeshire Gwynedd and Newcastle) are used in the present investigation. The sixth
29 centre (Liverpool) used a different design and is therefore excluded. Random samples of
30 people in their 65th year and above were obtained from Family Health Service Authority lists
31 (agency responsible for maintaining registers of general practice populations at that time).
32
33 The sample was stratified by age (65-74, and 75 years and over) and equal numbers were
34 randomly selected from these groups with the aim of recruiting 2500 to each centre. All study
35 centres obtained ethical approval from local research committees. (REC Ref: 05/MRE05/37).
36
37 Full details of methodology are available elsewhere.¹⁹
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52
53 Eligible participants (or their proxies where appropriate) provided informed consent. Trained
54 interviewers undertook baseline interviews in the participants' homes including socio-
55 demographic characteristics, cognitive function and disease history including previous
56
57
58
59
60

1
2
3 stroke, coronary heart disease and diabetes (full details at www.cfas.ac.uk). Based on
4
5 baseline screening, the study sample was divided into two groups at baseline: people without
6
7 cognitive impairment and a group consisting of those with cognitive impairment plus a
8
9 stratified subsample of those without cognitive impairment. The first group underwent no
10
11 further assessment at baseline and were ‘rescreened’ after two years. The second group
12
13 underwent a further detailed cognitive assessment at baseline, but were not followed up for
14
15 transient neurological symptoms. The estimates of prevalence of transient neurological
16
17 symptoms are calculated for all people at baseline, while the incidence estimates use only the
18
19 first group. All participants were flagged with the NHS Central Register. Deaths and
20
21 underlying causes of death attributed to stroke (ICD codes 430-438) were notified to the
22
23 study.
24
25
26
27

28 *Prevalence of transient neurological symptoms*

29
30 At baseline all participants were asked “Have you ever experienced sudden problems with:

- 31
32
33
34 (1) speech, which got better after a day?
35
36
37 (2) weakness in the arms or legs, which got better after a day?
38
39
40 (3) sight, which got better after a day?”
41
42
43

44 Social class was determined using the Registrar General’s Occupational Classification.
45
46 Cognitive status was determined using the Mini Mental State Examination (MMSE),²⁰ and
47
48 the Automated Geriatric Examination for Computer Assisted Taxonomy (AGECAT).²¹
49
50

51 *Incidence of transient neurological symptoms*

52
53 All those in the ‘rescreen’ arm were asked at two year follow-up if they had experienced each
54
55 transient neurological symptom in the past two years.
56
57
58
59
60

Analysis

All analyses were carried out using STATA version 11. Inverse probability weights were used throughout to ensure the sample was representative of the target population. Weights were estimated with logistic regression using presence in each phase of the study as an outcome and taking into account over-sampling of over-75s at baseline. Weights for incidence calculations adjust for attrition based on baseline characteristics and stratified selection into the assessment arm as appropriate. Baseline prevalence of each transient neurological symptom was calculated for age specific strata and as a weighted percentage to provide a population estimate of prevalence for people aged 65 and over. Associations with gender, age, social class (manual (IIIb, IV, V) and non-manual (I, II, IIIa)), and cardiovascular comorbidity were explored using logistic regression models adjusting for all other factors and cognitive function based on MMSE by score (less than 18, 18-21, 22-25 and 26-30).

Two year incidence of transient neurological symptoms was estimated using weighted percentages of those reporting any of the symptoms during follow-up. Weights were adjusted for refusals, drop-outs and for non-reassessment of people with cognitive impairment. Calculation of attrition weights for incident transient neurological symptoms excluded those who died between baseline and follow up. These estimates are therefore applicable to the population over 65 without severe cognitive impairment or stroke at baseline surviving at least two years.

RESULTS

The participation rate in the CFAS study was 80% (13,004/16,258). For the prevalence analysis, participants who had a stroke at baseline (963, 7.4%) or for whom baseline

1
2
3 information about stroke was missing (138, 1.1%) were excluded, leaving 11903 participants.
4
5 2,283 of the original participants were not allocated to the 'rescreen' arm at two years; 754
6
7 died, 1973 declined to participate and 145 were lost to follow-up, leaving 6,748 (76%
8
9 response rate of potential participants) for the incidence analysis.
10

11
12 Table 1 shows the demographic features of participants in the CFAS studied in this analysis
13
14 at baseline. 40% of participants were male and 60% of participants were female. 12.3% of all
15
16 participants reported at least one transient neurological symptom. 2.3% reported transient
17
18 loss of speech, 5.1% transient weakness and 7.6% transient loss of sight.
19
20

21
22 Table 2 shows prevalence data with weighted percentages and odds ratios (adjusted for age,
23
24 sex, social class, cognition and cardiovascular morbidities) of reported transient neurological
25
26 symptoms at baseline by demographic factors and comorbidities. 12.8% of males and 12.0%
27
28 of females reported at least one of the three transient neurological symptoms of loss of
29
30 speech, loss of sight, or weakness. There was no significant association of gender with
31
32 reporting at least one transient neurological symptom, but significantly lower odds of
33
34 reporting a transient neurological symptom in the over 85 age group. The odds of reporting
35
36 any transient neurological symptom were higher in those in manual compared to non-manual
37
38 social classes. The presence of cardiovascular morbidities of angina and heart attack were
39
40 also significantly associated with the odds of having at least one of the transient neurological
41
42 symptoms.
43
44
45
46
47
48
49
50

51
52 There was no difference between genders with regards to reporting individual transient
53
54 neurological symptoms of loss of speech, loss of sight or weakness. However, there was a
55
56 significantly lower odds of reporting transient visual loss in those over 85, and an increased
57
58 odds of reporting transient symptoms of weakness and loss of sight in manual compared to
59
60

1
2
3 non-manual social classes. The presence of cardiovascular co-morbidities of angina and heart
4
5 attack were associated with higher odds of all three symptoms.
6
7

8
9
10 Table 3 shows two year incidence of transient neurological symptoms in respondents
11
12 attending the “rescreen”. 9.8% of all participants reported at least one transient neurological
13
14 symptom over the 2 years, with the highest incidence of reported transient neurological
15
16 symptom being due to loss of sight followed by weakness, with loss of speech being the least
17
18 frequently reported transient neurological symptom. The incidence of each of the transient
19
20 neurological symptoms was highest in the 75 to 84 age group and lowest in the over 85 age
21
22 group.
23
24

25 26 27 **DISCUSSION**

28
29
30
31
32 Our findings suggest that transient neurological symptoms are common in the older
33
34 population in England and Wales, with at least 12% of people aged 65 and over having
35
36 experienced a transient neurological symptom of the arm or leg, speech or vision better after
37
38 a day, and approximately 5% experiencing at least one such symptom over the course of a
39
40 year. The commonest of these was transient symptoms of vision, followed by limb weakness.
41
42 Those over 85 reported lower rates of transient neurological symptoms, predominantly due to
43
44 less frequent reporting of transient visual loss. Problems of memory and recall may have
45
46 contributed to under-reporting, and higher mortality rates associated with neurological
47
48 incidents to underestimation of rates of transient neurological symptoms in this age group.
49
50 Chronic visual problems may have also potentially masked transient visual losses in the
51
52 oldest-old population. Incidence of at least one transient neurological symptom in the CFAS
53
54 population was approximately 2.6 times greater than that of confirmed TIA presenting to
55
56
57
58
59
60

1
2
3 medical services in the Oxford Vascular Study (OxVASC) in people aged over 85
4
5 (approximately 15 per 1000 per year), 8 times greater in those aged 75 to 84 (7 per 1000 per
6
7 year), and approximately 15 times greater in those aged 65 to 74 (3 per 1000 population per
8
9 year).¹⁰

11
12
13
14 The prevalence and incidence of transient neurological symptoms in the CFAS was
15
16 somewhat higher than those found by questionnaires used in other studies internationally
17
18 (mostly conducted in younger age groups), but comparable to those of Wilkinson et al. in an
19
20 over 60 age group in a US based study.^{7;12-14;16} Table 4 (online) shows the prevalence of
21
22 sudden onset of neurological symptoms of weakness in a limb or of loss of speech or sight in
23
24 previous population and community studies.^{7;12-14;16} Questions used to elicit transient
25
26 neurological symptoms in the CFAS are likely to have captured greater numbers of transient
27
28 neurological events in the population compared to those seeking more specific vascular
29
30 symptoms, or to the few studies defining more precisely the onset, offset and timing of the
31
32 event.^{7;12-14} While some respondents will have been describing true transient ischaemic
33
34 events, it is likely that many did not have a true TIA. Validated measures to determine the
35
36 presence of previous transient ischaemic attack are limited, and most studies of transient
37
38 neurological symptoms in questionnaires overestimate true transient ischaemic attacks.^{13;14;22}
39
40 Wilkinson et al. (1979) suggest that around 10% of transient symptoms reported in a
41
42 questionnaire are subsequently diagnosed as TIA after neurologist assessment.¹⁴ Self-
43
44 reported transient neurological symptoms in other community based studies have low
45
46 positive predictive value, with higher values only in studies in outpatient populations (over
47
48 70%).^{13;14;22-24} This suggests that the use of screening to identify possible past transient
49
50 ischaemic attacks may generate unnecessary extra strain on primary care and secondary TIA
51
52 services with limited benefit.
53
54
55
56
57
58
59
60

1
2
3
4
5 Patients presenting with transient neurological symptoms present considerable diagnostic
6 dilemmas for primary care practitioners reflected in low rates of TIA diagnosis confirmation
7 in patients referred to UK TIA clinics (over 50% being for non-TIA causes).^{6,25,26} Many
8 symptoms of TIA are non-specific and occur in non-vascular syndromes. Dizziness,
9 ophthalmological problems, migraine, epilepsy, nerve entrapment or psychological states are
10 the commonest non-TIA diagnoses.²⁵⁻²⁹ Often, however, no diagnosis can be determined.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

25:26 Scales such as the ABCD2² help determine the urgency of TIA referral, but do not distinguish TIA from non-TIA symptoms. Wilkinson et al. reported transient loss of speech and loss of sight to be more reliable than limb weakness for neurologist diagnosis of TIA,¹⁴ while Hart et al. found the strongest and most consistent relationship with subsequent stroke to be loss of power in an arm.⁷ Other studies suggest that the presence of certain symptoms such as headache, dizziness, loss of consciousness, memory loss, blurred vision, generalised weakness, pain in limbs and seizures make the diagnosis of TIA less likely.^{14,29,30}

Study limitations

The incidence of transient neurological symptoms was determined in people without severe cognitive impairment, and may be an underestimate since cognitive impairment can be a manifestation of vascular disease.^{31,32} Only three transient neurological symptoms were reported in this study. Some symptoms of TIA (e.g. posterior circulation or pure sensory symptoms) were not sought. The wording of questions to identify transient neurological symptoms may have picked up some people who had symptoms lasting more than 24 hours. Such patients are nevertheless likely to draw on TIA services for further assessment. In addition, it was not possible to determine whether different transient neurological symptoms in a participant occurred simultaneously or separately in time. The problem of recall bias in

1
2
3 these self-reports of transient symptoms needs to be considered. Questions were designed to
4 be easily comprehensible to the older population. However, the need to consider multiple
5 criteria when responding to a question e.g. “sudden onset” and “less than a day”, may have
6 led to difficulties in interpretation of the transient neurological symptoms questions for some
7 participants. Finally, baseline and two year follow-up were carried out in the 1990s and
8 changes in rates of vascular events may have occurred since then. While the age-specific
9 incidence of stroke appears to be declining, it is not clear that the same is true of TIA.^{10,33,34}
10
11 As well, this study is more recent than many studies estimating rates of transient neurological
12 symptoms in the population, many of which have been carried out during the 1970’s or ‘80’s.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusion

In a large multi-centred community based study highly representative of the older population in the UK and conducted in the age group where TIAs are most common, we found a high prevalence and incidence of transient neurological symptoms. The incidence of such symptoms in the community is significantly greater than that of TIAs. This highlights the need for adequate provision of TIA services and the potential importance of the development of valid diagnostic tools to assist the general practitioner and hospital doctor in better triage of people presenting with transient neurological symptoms.

ACKNOWLEDGEMENTS

We thank the MRC CFAS study group for data collection and management. We are also grateful to all respondents, their families and their primary care teams from across the country for their participation in MRC CFAS.

COMPETING INTERESTS

"All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work."

FUNDING

The MRC CFAS Study has had funding by major awards from the Medical Research Council (MRC/G9901400) and Department of Health. NM was funded by a National Institute for Health Research (NIHR) Walport Clinical Lectureship in Primary Care Research. None of the sponsors influenced the design or conduct of the study or the analysis or interpretation of the findings. All researchers acted independently from funders in the design and carrying out of this study.

AUTHORS CONTRIBUTIONS

CB is Principal Investigator of the MRC CFAS Study. NM and GS contributed to analysis of data. All authors contributed to study design and intellectual input. All authors, external and internal, had full access to all of the data (including statistical reports and tables) and can take responsibility for the integrity of the data and accuracy of the data analysis.

DATA SHARING

Data sharing through application.

Reference List

- (1) Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. *BMJ* 2004; 328(7435):326.
- (2) Rothwell PM, Giles MF, Flossmann E, et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. *Lancet* 2005; 366(9479):29-36.
- (3) Rothwell PM, Giles MF, Chandratheva A, et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. *Lancet* 2007; 370(9596):1432-1442.
- (4) Department of Health. Department of Health. National Stroke Strategy. 2007.
- (5) Department of Health. Stroke: Act F.A.S.T. awareness campaign. 2009. Department of Health.
- (6) Giles MF, Rothwell PM. Substantial underestimation of the need for outpatient services for TIA and minor stroke. *Age Ageing* 2007; 36(6):676-680.
- (7) Hart CL, Hole DJ, Smith GD. The relation between questions indicating transient ischaemic attack and stroke in 20 years of follow up in men and women in the Renfrew/Paisley Study. *J Epidemiol Community Health* 2001; 55(9):653-656.
- (8) Mant J, Wade DT, Winner S. Health care needs assessment: stroke. In: Stevens A, Raftery J, Mant J, Simpson S, editors. Health care needs assessment: the epidemiologically based needs assessment reviews. 2nd ed. Oxford: Radcliffe Medical Press; 2004. 141-244.
- (9) Orlandi G, Gelli A, Fanucchi S, et al. Prevalence of stroke and transient ischaemic attack in the elderly population of an Italian rural community. *Eur J Epidemiol* 2003; 18(9):879-882.
- (10) Rothwell PM, Coull AJ, Silver LE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). *Lancet* 2005; 366(9499):1773-1783.
- (11) Bos MJ, van Rijn MJ, Witteman JC, et al. Incidence and prognosis of transient neurological attacks. *JAMA* 2007; 298(24):2877-2885.
- (12) Mules J, Henderson M, Kuller L. A population survey of symptoms suggestive of transient ischemic attacks. *Stroke* 1971; 2(2):114-127.
- (13) Toole JF, Lefkowitz DS, Chambless LE, et al. Self-reported transient ischemic attack and stroke symptoms: methods and baseline prevalence. The ARIC Study, 1987-1989. *Am J Epidemiol* 1996; 144(9):849-856.

- 1
2
3 (14) Wilkinson WE, Heyman A, Burch JG, et al. Use of a self-administered questionnaire
4 for detection of transient cerebral ischemic attacks: I. Survey of elderly persons living
5 in retirement facilities. *Ann Neurol* 1979; 6(1):40-46.
6
7 (15) Bots ML, van der Wilk EC, Koudstaal PJ, et al. Transient neurological attacks in the
8 general population. Prevalence, risk factors, and clinical relevance. *Stroke* 1997;
9 28(4):768-773.
10
11 (16) Howard VJ, McClure LA, Meschia JF, et al. High prevalence of stroke symptoms
12 among persons without a diagnosis of stroke or transient ischemic attack in a general
13 population: the REasons for Geographic And Racial Differences in Stroke
14 (REGARDS) study. *Arch Intern Med* 2006; 166(18):1952-1958.
15
16 (17) van Wijk I, Kappelle LJ, van GJ, et al. Long-term survival and vascular event risk
17 after transient ischaemic attack or minor ischaemic stroke: a cohort study. *Lancet*
18 2005; 365(9477):2098-2104.
19
20 (18) Clark TG, Murphy MF, Rothwell PM. Long term risks of stroke, myocardial
21 infarction, and vascular death in "low risk" patients with a non-recent transient
22 ischaemic attack. *J Neurol Neurosurg Psychiatry* 2003; 74(5):577-580.
23
24 (19) Brayne C, McCracken C, Matthews FE. Cohort profile: the Medical Research Council
25 Cognitive Function and Ageing Study (CFAS). *Int J Epidemiol* 2006; 35(5):1140-
26 1145.
27
28 (20) Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for
29 grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975;
30 12(3):189-198.
31
32 (21) Copeland JR, Dewey ME, Griffiths-Jones HM. A computerized psychiatric diagnostic
33 system and case nomenclature for elderly subjects: GMS and AGE-CAT. *Psychol Med*
34 1986; 16(1):89-99.
35
36 (22) Lasserson DS. Initial management of suspected transient cerebral ischaemia and
37 stroke in primary care: implications of recent research. *Postgrad Med J* 2009;
38 85(1006):422-427.
39
40 (23) Jones WJ, Williams LS, Meschia JF. Validating the Questionnaire for Verifying
41 Stroke-Free Status (QVSFS) by neurological history and examination. *Stroke* 2001;
42 32(10):2232-2236.
43
44 (24) Wilson A, Potter J, Taub N, et al. The effectiveness of a modified version of the
45 Wilkinson questionnaire in screening for TIA and minor stroke in the United
46 Kingdom. *Age Ageing* 2005; 34(1):30-35.
47
48 (25) Murray S, Bashir K, Lees KR, et al. Epidemiological aspects of referral to TIA clinics
49 in Glasgow. *Scott Med J* 2007; 52(1):4-8.
50
51 (26) Martin PJ, Young G, Enevoldson TP, et al. Overdiagnosis of TIA and minor stroke:
52 experience at a regional neurovascular clinic. *QJM* 1997; 90(12):759-763.
53
54
55
56
57
58
59
60

- 1
2
3 (27) Boysen G, Jensen G, Schnohr P. Frequency of focal cerebral transient ischemic
4 attacks during a 12 month period. The Copenhagen city heart study. *Stroke* 1979;
5 10(5):533-534.
6
7 (28) Johnson SE, Skre H. Transient cerebral ischemic attacks in the young and middle
8 aged. A population study. *Stroke* 1986; 17(4):662-666.
9
10 (29) Amort M, Fluri F, Schafer J, et al. Transient ischemic attack versus transient ischemic
11 attack mimics: frequency, clinical characteristics and outcome. *Cerebrovasc Dis*
12 2011; 32(1):57-64.
13
14 (30) Dawson J, Lamb KE, Quinn TJ, et al. A recognition tool for transient ischaemic
15 attack. *QJM* 2009; 102(1):43-49.
16
17 (31) De Haan EH, Nys GM, van Zandvoort MJ. Cognitive function following stroke and
18 vascular cognitive impairment. *Curr Opin Neurol* 2006; 19(6):559-564.
19
20 (32) Selnes OA, Vinters HV. Vascular cognitive impairment. *Nat Clin Pract Neurol* 2006;
21 2(10):538-547.
22
23 (33) Dennis MS, Bamford JM, Sandercock PA, et al. Incidence of transient ischemic
24 attacks in Oxfordshire, England. *Stroke* 1989; 20(3):333-339.
25
26 (34) Rothwell PM, Coull AJ, Giles MF, et al. Change in stroke incidence, mortality, case-
27 fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford
28 Vascular Study). *Lancet* 2004; 363(9425):1925-1933.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Demographics of Participants in the Cognitive Function and Aging Study (CFAS)
by sex, age, social class and comorbidity (Data are count (%))

	All (n=11903)		Males (n=4689)		Females (n=7214)	
	N	%*	N	%*	N	%*
Age						
65-74	5980	58.8	2635	64.5	3345	55.0
75-84	4624	32.1	1716	29.6	2908	33.8
85+	1299	9.1	338	5.9	961	11.2
Social Class						
I	558	4.8	225	4.8	333	4.8
II	2988	26.1	1213	26.3	1775	25.9
IIIa	1337	11.6	456	9.9	881	12.8
IIIb	4295	37.7	1865	40.8	2430	35.5
IV	1727	14.9	650	13.9	1077	15.7
V	561	4.9	196	4.3	365	5.3
Comorbidity						
Angina	1923	16.3	878	15.3	1045	11.1
Diabetes	672	5.5	310	6.4	362	4.9
Heart Attack	1139	9.5	632	13.6	507	6.8

*Weighted percentages

Table 2: Distribution and adjusted odds of transient neurological symptoms in those aged 65 or over in the Cognitive Function and Aging Study (CFAS) by sex, social class and comorbidity (Data are count (%))

	Loss of Speech			Weakness			Loss of Sight			At least one symptom		
	N	%*	OR † (95%CI)	N	%*	OR † (95%CI)	N	%*	OR † (95%CI)	N	%*	OR † (95%CI)
Gender												
Male	119	2.5	1.0	257	5.5	1.0	347	7.6	1.0	598	12.8	1.0
Female	152	2.2	0.9(0.7-1.2)	339	4.8	0.9(0.7-1.0)	525	7.6	1.0(0.9-1.2)	858	12.0	1.0 (0.9-1.1)
Age												
65-74	137	2.3	1.0	302	5.1	1.0	480	8.1	1.0	768	12.9	1.0
75-84	104	2.3	0.7(0.7-1.2)	229	5.0	0.9 (0.7-1.1)	327	7.2	0.9(0.7-1.1)	553	12.0	0.9 (0.8-1.0)
85+	30	2.5	0.8(0.5-1.3)	65	5.4	0.9(0.6-1.2)	65	5.4	0.6(0.5-0.8)	134	10.4	0.7 (0.6-0.9)
Social Class												
Non-manual	96	5.8	1.0	63	11.0	1.0	295	17.9	1.0	497	10.2	1.0
Manual	164	7.2	1.1 (0.9-1.5)	390	17.8	1.4 (1.2-1.7)	556	25.7	1.4(1.2-1.6)	920	14.1	1.4 (1.2-1.6)
Comorbidity												

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Angina (n=1538)	64	4.3	1.5(1.0-2.2)	176	11.7	2.5(2.0-3.2)	160	10.6	1.3(1.0-1.6)	312	20.7	1.7(1.4-1.9)
Diabetes (n=672)	28	4.0	1.4(0.9-2.2)	40	6.1	1.0(0.7-1.4)	66	10.1	1.3(0.9-1.7)	102	15.2	1.1(0.9-1.4)
Heart Attack (n=1139)	52	4.7	1.8(1.2-2.7)	131	10.5	1.4(1.2-1.9)	119	11.5	1.4(1.1-1.8)	233	12.4	1.4(1.2-1.8)

* Weighted percentages

† Adjusted for age, sex, social class, cognition and cardiovascular comorbidities

‡ Reference non-manual (I,II, IIIa) compared to manual social class (IIIb,IV,V)

156 participants had missing data on the speech questionnaire, 155 on the weakness and 154 on the sight question

Table 3: Two year incidence of transient neurological symptoms in CFAS in those without stroke at baseline at two yr Screening Assessment, N at 2yrs= 6748 (Data are N (%))

Transient Neurological Symptom	Age							
	All		65-74		75-84		85+	
	N=3657		N=2618		N=2618		N=473	
	N	%*	N	%*	N	%*	N	%*
Loss of Speech	149	2.1	55	1.5	84	3.3	10	2.0
Weakness	239	3.7	117	3.4	106	4.1	16	3.4
Loss of Sight	410	6.3	214	6.3	170	6.6	26	4.5
At least one	675	9.8	327	9.3	304	11.6	44	7.8

*Weighted percentage

98 participants had missing data on the speech questionnaire, 97 on the weakness and 105 on the sight question

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 4: Epidemiological studies of self-reported prevalence of sudden neurological symptoms of weakness of limbs, loss of sight and loss of speech

Study	Age Range	Date	Population	N	Question	How	Frequencies
-------	-----------	------	------------	---	----------	-----	-------------

For peer review only

Table 4a: Frequencies of self-reported sudden weakness of limbs across population studies

Renfrew/ Paisley <i>Hart et al. (2001)</i> ¹	45-64	1972-1976	General population study residents Renfrew&Paisley, Scotland Excluded those with stroke	1511 3	Have you ever without warning suddenly lost the power of an arm?	Questionnaire checked when attended a clinic	344 (2.3%)
Renfrew/ Paisley <i>Hart et al. (2001)</i> ¹	45-64	1972-1976	General population study residents Renfrew&Paisley, Scotland Excluded those with stroke	1511 3	Have you ever without warning suddenly lost the power of a leg?	Questionnaire checked when attended a clinic	363 (2.4%)
Atherosclerosis Risk in Communities (ARIC) Cohort <i>Toole et al (1996)</i> ²	45-64	1987-1989	Four centres in US adults residents	12,205	Have you ever had sudden painless weakness on one side of your body?	Administered by researcher – questions read aloud	283 (2.3%)
Baltimore population study <i>Mules et al (1971)</i> ³	>40	1954-1967	Population samples – two in US	9937	Paralysis within 2 years prior to interview	Interview by trained interviewer	48(0.7%)
Reasons for geographic and racial differences in Stroke (REGARDS) <i>Howard et al (2006)</i> ⁴	> 45 (mean 65)	2003	Community dwelling individuals in US. Those with stroke and TIA excluded	1846 2	Have you ever had sudden painless weakness on one side of the body?	QVSFS questionnaire – telephone and in person	1065 (5.8%)
Survey of Elderly Persons Living in Retirement Facilities <i>Wilkinson et al (1979)</i> ⁵	>60	Published 1979	Elderly living in retirement facilities in 8 cities in the US	7281	During last 12 months any sudden occurrence of transient episode of weakness or paralysis of limbs <i>which subsequently cleared up completely</i>	Self-administered questionnaire	197 (2.7%)

Table 4b: Frequencies of self-reported sudden speech impairment across population studies

Study	Age Range	Date	Population	N	Question	How	Frequencies
Renfrew/ Paisley <i>Hart et al. (2001)</i> ¹	45-64	1972-1976	General population study residents Renfrew&Paisley, Scotland Excluded those with stroke	15113	Have you ever without warning suddenly been unable to speak properly?	Questionnaire checked when attended a clinic	270 (1.8%)
Atherosclerosis Risk in Communities (ARIC) Cohort <i>Toole et al (1996)</i> ²	45-64	1987-1989	Four centres in US adults residents	12,205	Have you ever had sudden episode of “speech dysfunction”?	Administered by researcher – questions read aloud	313 (2.6%)
Reasons for geographic and racial differences in Stroke (REGARDS) <i>Howard et al (2006)</i> ⁴	> 45 (mean 65)	2003	Community dwelling individuals in US. Those with stroke and TIA excluded	18462	Have you ever had sudden loss of ability to express self verbally (or in writing)?	QVSFS questionnaire – telephone and in person	698 (3.8%)
Survey of Elderly Persons Living in Retirement Facilities <i>Wilkinson et al (1979)</i> ⁵	>60	Published 1979	Elderly living in retirement facilities in 8 cities in the US	7281	During last 12 months experienced any sudden loss of speech or changes in speech <i>which subsequently cleared up completely?</i>	Self-administered questionnaire	149 (2.0%)

Table 4c: Frequencies of self-reported sudden visual impairment across population studies

Study	Age Range	Date	Population	N	Question	How	Frequencies
Atherosclerosis Risk in Communities (ARIC) Cohort <i>Toole et al (1996)</i> ²	45-64	1987-1989	Four centres in US adults residents	12,205	Have you ever had sudden “visual impairment”?	Administered by researcher – questions read aloud	313 (2.6%)
Reasons for geographic and racial differences in Stroke (REGARDS) <i>Howard et al (2006)</i> ⁴	> 45 (mean 65)	2003	Community dwelling individuals in US. Those with stroke and TIA excluded	18462	Have you ever had sudden painless loss of vision in one or both eyes?	QVSFS questionnaire – telephone and in person	698 (3.8%)
Baltimore population study <i>Mules et al (1971)</i> ³	>40	1954-1967	Population samples – two in US	9937	Loss of vision within 2 years prior to interview	Interview by trained interviewer	129 (2.0%)
Survey of Elderly Persons Living in Retirement Facilities <i>Wilkinson et al (1979)</i> ⁵	>60	Published 1979	Elderly living in retirement facilities in 8 cities in the US	7281	During last 12 months experienced sudden loss of eyesight <i>which subsequently cleared up completely?</i>	Self-administered questionnaire	149 (2.0%)

- 1
2
3
4
5 (1) Hart CL, Hole DJ, Smith GD. The relation between questions indicating
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
transient ischaemic attack and stroke in 20 years of follow up in men and
women in the Renfrew/Paisley Study. *J Epidemiol Community Health* 2001;
55(9):653-656.
- (2) Toole JF, Lefkowitz DS, Chambless LE, Wijnberg L, Paton CC, Heiss G.
Self-reported transient ischemic attack and stroke symptoms: methods and
baseline prevalence. The ARIC Study, 1987-1989. *Am J Epidemiol* 1996;
144(9):849-856.
- (3) Mules J, Henderson M, Kuller L. A population survey of symptoms suggestive
of transient ischemic attacks. *Stroke* 1971; 2(2):114-127.
- (4) Howard VJ, McClure LA, Meschia JF, Pulley L, Orr SC, Friday GH. High
prevalence of stroke symptoms among persons without a diagnosis of stroke or
transient ischemic attack in a general population: the REasons for Geographic
And Racial Differences in Stroke (REGARDS) study. *Arch Intern Med* 2006;
166(18):1952-1958.
- (5) Wilkinson WE, Heyman A, Burch JG, Ostfeld A, Labarthe DR, Leviton A et
al. Use of a self-administered questionnaire for detection of transient cerebral
ischemic attack

1
2
3
4 **Transient neurological symptoms in the older population: Report of**
5 **a prospective cohort study - the Medical Research Council Cognitive**
6 **Function and Ageing Study (CFAS)**
7
8
9

10
11 **Nahal Mavaddat, George M Savva, Daniel Lasserson, Matthew**
12 **Giles, Carol Brayne, Jonathan Mant**
13

14
15
16
17 **Department of Public Health and Primary Care, University of**
18 **Cambridge, Strangeways Laboratory, Worts Causeway, Cambridge,**
19 **UK CB1 8RN Nahal Mavaddat clinical lecturer Jonathan Mant**
20 **professor**
21

22
23 ~~**The Irish Longitudinal Study on Ageing, Department of**~~
24 ~~**Gerontology, Trinity College Dublin, Lincoln Gate, Dublin 2,**~~
25 ~~**Republic of Ireland**~~ **School of Nursing Sciences, University of East**
26 **Anglia, Norwich Research Park, Norwich, UK, NR4 7TJ.** George
27 Savva senior lecturer
28
29

30
31 **Department of Primary Care Health Sciences, University of Oxford,**
32 **Oxford, U.K. New Radcliffe House, 2nd floor, Walton Street,**
33 **Jericho, UK OX2 6NW Daniel Lasserson clinical lecturer**
34

35
36 **Stroke Prevention Research Unit, NIHR Biomedical Research**
37 **Centre, Oxford University, Department of Clinical Neurology, John**
38 **Radcliffe Hospital, Oxford, UK OX3 9DU Matthew Giles consultant**
39 **physician**
40
41

42
43 **Department of Public Health and Primary Care, University of**
44 **Cambridge, Institute of Public Health, Forvie Site, Robinson Way**
45 **Causeway, Cambridge, UK CB2 0SR Carol Brayne professor**
46
47

48
49 **Correspondence to: Nahal Mavaddat nm212@medschl.cam.ac.uk**
50
51

52
53
54 The Corresponding Author has the right to grant on behalf of all authors and does
55 grant on behalf of all authors, an exclusive licence (or non exclusive for government
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJ PGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence.

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2013-003195 on 24 July 2013. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Article Summary

Article Focus:

- Prompt initiation of secondary prevention following TIA is associated with up to 80% reduction in risk of subsequent stroke.
- Many people presenting to specialist TIA clinics with transient neurological symptoms do not have TIA.
- The prevalence and incidence of transient neurological symptoms (as opposed to TIA) in older age groups is unknown.

Key Messages:

- In a large multi-centred community based study representative of the older population in the UK, we found a high prevalence and incidence of transient neurological symptoms, significantly greater than that of TIAs [in hospital and population-based studies](#).
- ~~The [high rates of transient neurological symptoms in the community in the older population should be considered when planning TIA services](#) highlights the need for adequate provision of TIA services and better diagnostic tools, as the public becomes more sensitised to possible cerebrovascular symptoms, and primary care practitioners more aware of the potential benefits of rapid response to suspected TIA.~~

Strengths and Limitations of this study:

- Strengths - Previous studies of incidence and prevalence of transient neurological symptoms have mostly been conducted in populations not

1
2
3 representative of older age groups where TIA is most common and few have
4
5 been undertaken in UK populations.
6

- 7 • Limitations - The incidence of transient neurological symptoms in the study
8
9 was determined in people without severe cognitive impairment, and may be an
10
11 underestimate since cognitive impairment can be a manifestation of vascular
12
13 disease. The wording of questions to identify transient neurological symptoms
14
15 may have picked up some people who had symptoms lasting more than 24
16
17 hours. ~~Such patients are nevertheless likely to draw on TIA services for~~
18
19 ~~further assessment.~~
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective: Transient ischaemic attack (TIA) is a recognised risk factor for stroke in the older population requiring timely assessment and treatment by a specialist. The need for such TIA services is driven by the epidemiology of transient neurological symptoms, which may not be caused by TIA. We report prevalence and incidence of transient neurological symptoms in a large UK cohort study of older people. **Design** Longitudinal cohort study **Setting and Participants:** The MRC Cognitive Function and Aging Study (CFAS) is a population representative study derived from random samples of people in their 65th year. Interview at baseline included questions about stroke and [three](#) transient neurological symptoms, repeated in a sub-sample after two years. Patients were flagged for mortality. **Main Outcome Measures** Prevalence and two year incidence of transient neurological symptoms. **Results** In 11,903 participants without [a](#) history of stroke, 271(2.3%) reported transient problems with speech, 872 (7.6%) with sight, and 596 (5.1%) weakness in a limb, with 1456 (12.7%) reporting at least one symptom. Of those re-interviewed (n=6748), 675 (9.8%) reported at least one symptom over two years. **Conclusions** Lifetime prevalence and incidence of transient neurological symptoms in people 65 and over [is high](#) and [is](#) substantially [greater higher](#) than [the](#) incidence of TIA in hospital and population-based studies. [These high rates of transient neurological symptoms in the community in the older population should be considered when planning TIA services. With increasing public education regarding stroke, TIA services may need to cope with an increase in demand as a greater proportion of people with transient neurological symptoms present for urgent assessment.](#)

INTRODUCTION

Transient ischaemic attack (TIA) is an established and powerful risk factor for stroke. 8% of patients who have a TIA suffer a stroke within 7 days, many within 48 hours.^{1;2} Immediate specialist assessment and treatment is associated with substantial reductions in this early risk of stroke,³ and is recommended for people with suspected TIA.⁴

As awareness grows of the urgency of early management of TIA amongst both primary care practitioners and the general public,⁵ more patients with symptoms suggestive of a TIA are likely to present to primary and secondary care services. Need for specialist services will be driven by incidence of symptoms that might represent TIA (i.e. transient neurological symptoms) rather than the epidemiology of TIA *per se*. Currently about 48,000 probable or definite TIAs (transient neurological symptoms lasting less than 24 hours of likely vascular aetiology), and 43,000 minor strokes (stroke events causing minimal or no neurological deficits) are managed as outpatients every year in England, but it is not clear to what extent this might be the tip of the iceberg.⁶ Data are available worldwide on the prevalence and incidence of TIA.⁷⁻¹¹ The epidemiology in the community of transient neurological symptoms (i.e. neurological symptoms of sudden onset of which TIA is a subset), is however less well defined. Previous studies of incidence and prevalence of transient neurological symptoms, have mostly been conducted in populations not representative of older age groups where TIA is most common.^{7;11-16} Very few have been undertaken in UK populations. While incidence of transient neurological symptoms will drive need for specialist TIA services, prevalence of transient neurological symptoms in the

1
2
3 community is also important. TIA is associated with a long term increase in risk of
4 stroke,^{17;18} so there may be value in diagnosing 'old' events that have not presented
5
6
7 to medical services in order to target secondary prevention. Hence the need to know
8
9
10 both the incidence and prevalence of transient neurological symptoms in the
11
12 community.

13
14
15
16 This study reports prevalence and incidence of three common transient neurological
17
18 symptoms (limb weakness, loss of speech and disturbance of vision) in a population
19
20 based multi-centred cohort study in the UK (England and Wales) in those aged 65 and
21
22 over, the Medical Research Council Cognitive Function and Ageing Study (CFAS).¹⁹
23
24
25
26

27 METHODS

28
29 The Medical Research Council CFAS is a population ~~based-representative~~ study of
30
31 individuals aged 65 years and over ~~living in the community~~. The study began in 1991
32
33 and was designed to determine the incidence of dementia in the older population. It
34
35 has six centres across England and Wales chosen to represent the national variation of
36
37 urban-rural mix, socio-economic deprivation and rates of chronic disease.¹⁹ Five of
38
39 these with identical study designs (Oxford, Nottingham, Cambridgeshire Gwynedd
40
41 and Newcastle) are used in the present investigation. The sixth centre (Liverpool)
42
43 used a different design and is therefore excluded. Random samples of people in their
44
45 65th year and above were obtained from Family Health Service Authority lists
46
47 (agency responsible for maintaining registers of general practice populations at that
48
49 time). The sample was stratified by age (65-74, and 75 years and over) and equal
50
51 numbers were randomly selected from these groups with the aim of recruiting 2500 to
52
53 each centre. All study centres obtained ethical approval from local research
54
55
56
57
58
59
60

1
2
3 committees. (REC Ref: 05/MRE05/37). Full details of methodology are available
4
5 elsewhere.¹⁹
6
7

8 Eligible participants ~~(or their proxies where appropriate)~~ provided informed consent
9 ~~(or their proxies where appropriate)~~. Trained interviewers undertook baseline
10 interviews in the participants' homes including socio-demographic characteristics,
11 cognitive function and disease history including previous stroke, coronary heart
12 disease and diabetes (full details at www.cfas.ac.uk). Based on baseline screening, the
13 study sample was divided into two groups at baseline: people without cognitive
14 impairment and a group consisting of those with cognitive impairment plus a
15 stratified subsample of those without cognitive impairment. The first group
16 underwent no further assessment at baseline and were 'rescreened' after two years.
17 The second group underwent a further detailed cognitive assessment at baseline, but
18 were not followed up for transient neurological symptoms. The estimates of
19 prevalence of transient neurological symptoms are calculated for all people at
20 baseline, while the incidence estimates use only the first group. All participants were
21 flagged with the NHS Central Register. Deaths and underlying causes of death
22 attributed to stroke (ICD codes 430-438) were notified to the study.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 *Prevalence of transient neurological symptoms*

43 At baseline all participants were asked "Have you ever experienced sudden problems
44 with:
45
46
47
48

49 (1) speech, which got better after a day?
50
51

52 (2) weakness in the arms or legs, which got better after a day?
53
54

55 (3) sight, which got better after a day?"
56
57
58
59
60

1
2
3 Social class was determined using the Registrar General's Occupational
4 Classification. Cognitive status was determined using the Mini Mental State
5 Examination (MMSE),²⁰ and the Automated Geriatric Examination for Computer
6 Assisted Taxonomy (AGECAT).²¹
7
8
9
10

11 *Incidence of transient neurological symptoms*

12
13 All those in the 'rescreen' arm were asked at two year follow-up if they had
14 experienced each transient neurological symptom in the past two years.
15
16
17
18
19

20 **Analysis**

21
22 All analyses were carried out using STATA version 11. Inverse probability weights
23 were used throughout to ensure the sample was representative of the target
24 population. Weights were estimated with logistic regression using presence in each
25 phase of the study as an outcome and taking into account over-sampling of over-75s
26 at baseline. Weights for incidence calculations adjust for attrition based on baseline
27 characteristics and stratified selection into the assessment arm as appropriate.
28
29 Baseline prevalence of each transient neurological symptom was calculated for age
30 specific strata and as a weighted percentage to provide a population estimate of
31 prevalence for people aged 65 and over. Associations with gender, age, social class
32 (manual (IIIb, IV, V) and non-manual (I, II, IIIa)), and cardiovascular comorbidity
33 were explored using logistic regression models adjusting for all other factors and
34 cognitive function based on MMSE by score (less than 18, 18-21, 22-25 and 26-30).
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51
52 Two year incidence of transient neurological symptoms was estimated using weighted
53 percentages of those reporting any of the symptoms during follow-up. Weights were
54 adjusted for refusals, drop-outs and for non-reassessment of people with cognitive
55
56
57
58
59
60

1
2
3 impairment. Calculation of attrition weights for incident transient neurological
4 symptoms excluded those who died between baseline and follow up. These estimates
5 are therefore applicable to the population over 65 without severe cognitive
6 impairment or stroke at baseline surviving at least two years.
7
8
9
10

11 12 13 **RESULTS**

14
15
16 The participation rate in the CFAS study was 80% (13,004/16,258). For the
17 prevalence analysis, participants who had a stroke at baseline (963, 7.4%) or for
18 whom baseline information about stroke was missing (138, 1.1%) were excluded,
19 leaving 11903 participants. 2,283 of the original participants were not allocated to the
20 'rescreen' arm at two years; 754 died, 1973 declined to participate and 145 were lost
21 to follow-up, leaving 6,748 (76% response rate of potential participants) for the
22 incidence analysis.
23
24
25
26
27
28
29
30
31

32
33 Table 1 shows the demographic features of participants in the CFAS studied in this
34 analysis at baseline. 40% of participants were male and 60% of participants were
35 female. 12.3% of all participants reported at least one transient neurological
36 symptom. 2.3% reported transient loss of speech, 5.1% transient weakness and 7.6%
37 transient loss of sight.
38
39
40
41
42
43
44
45

46 Table 2 shows prevalence data with weighted percentages and odds ratios (adjusted
47 for age, sex, social class, cognition and cardiovascular morbidities) of reported
48 transient neurological symptoms at baseline by demographic factors and
49 comorbidities. 12.8% of males and 12.0% of females reported at least one of the three
50 transient neurological symptoms of loss of speech, loss of sight, or weakness. There
51 was no significant association of gender with reporting at least one transient
52
53
54
55
56
57
58
59
60

1
2
3 neurological symptom, but significantly lower odds of reporting a transient
4
5 neurological symptom in the over 85 age group. ~~Problems of memory and recall may~~
6
7 ~~have contributed to under-reporting in this group. Greater rates of mortality~~
8
9 ~~associated with neurological incidents in the oldest old population may also lead to~~
10
11 ~~under-estimation of rates of transient neurological symptoms.~~ The odds of reporting
12
13 any transient neurological symptom were higher in those in manual compared to non-
14
15 manual social classes. The presence of cardiovascular morbidities of angina and heart
16
17 attack were also significantly associated with the odds of having at least one of the
18
19 transient neurological symptoms.
20
21
22
23
24

25
26 There was no difference between genders with regards to reporting individual
27
28 transient neurological symptoms of loss of speech, loss of sight or weakness.
29
30 However, there was a significantly lower odds of reporting transient visual loss in
31
32 those over 85, and. ~~This may partly explain the overall lower prevalence of reporting~~
33
34 ~~at least one transient neurological symptom in this group. The cause for this is~~
35
36 ~~unclear, however in addition to problems of recall, may in part relate to the greater~~
37
38 ~~likelihood of chronic visual problems potentially masking transient visual losses in~~
39
40 ~~the oldest old population.~~ an increased odds of reporting transient symptoms of
41
42 weakness and loss of sight in manual compared to non-manual social classes. The
43
44 presence of cardiovascular co-morbidities of angina and heart attack were associated
45
46 with higher odds of all three symptoms.
47
48
49
50

51
52 Table 3 shows two year incidence of transient neurological symptoms in respondents
53
54 attending the “rescreen”. 9.8% of all participants reported at least one transient
55
56 neurological symptom over the 2 years, with the highest incidence of reported
57
58
59
60

1
2
3 transient neurological symptom being due to loss of sight followed by weakness, with
4
5 loss of speech being the least frequently reported transient neurological symptom. The
6
7 incidence of each of the transient neurological symptoms was highest in the 75 to 84
8
9 age group and lowest in the over 85 age group.
10

11 12 13 14 **DISCUSSION**

15
16
17
18 Our findings suggest that transient neurological symptoms are common in the older
19
20 population in England and Wales, with at least 12% of people aged 65 and over
21
22 having experienced a transient neurological symptom of the arm or leg, speech or
23
24 vision better after a day, and approximately 5% experiencing at least one such
25
26 symptom over the course of a year. The commonest of these was transient symptoms
27
28 of vision, followed by limb weakness. [Those over 85 reported lower rates of transient
29
30 neurological symptoms, predominantly due to less frequent reporting of transient
31
32 visual loss. Problems of memory and recall may have contributed to under-reporting,
33
34 and higher mortality rates associated with neurological incidents to underestimation
35
36 of rates of transient neurological symptoms in this age group. Chronic visual
37
38 problems may have also potentially masked transient visual losses in the oldest-old
39
40 population.](#) Incidence of at least one transient neurological symptom in the CFAS
41
42 population was approximately 2.6 times greater than that of confirmed TIA
43
44 [presenting to medical services](#) in the Oxford Vascular Study (OxVASC) in people
45
46 aged over 85 (approximately 15 per 1000 per year), 8 times greater in those aged 75
47
48 to 84 (7 per 1000 per year), and approximately 15 times greater in those aged 65 to 74
49
50 (3 per 1000 population per year).¹⁰
51
52
53
54
55
56
57
58
59
60

1
2
3 The prevalence and incidence of transient neurological symptoms in the CFAS was
4 somewhat higher than those found by questionnaires used in other studies
5 internationally (mostly conducted in younger age groups), but comparable to those of
6 Wilkinson et al. in an over 60 age group in a US based study.^{7;12-14;16} Table 4 (online)
7 shows the prevalence of sudden onset of neurological symptoms of weakness in a
8 limb or of loss of speech or sight in previous population and community studies.<sup>7;12-
9 14;16</sup> Questions used to elicit transient neurological symptoms in the CFAS are likely
10 to have captured greater numbers of transient neurological events in the population
11 compared to those seeking more specific vascular symptoms, or to the few studies
12 defining more precisely the onset, offset and timing of the event.^{7;12-14} While some
13 respondents will have been describing true transient ischaemic events, it is likely that
14 many did not have a true TIA. Validated measures to determine the presence of
15 previous transient ischaemic attack are limited, and most studies of transient
16 neurological symptoms in questionnaires overestimate true transient ischaemic
17 attacks.^{13;14;22} Wilkinson et al. (1979) suggest that around 10% of transient symptoms
18 reported in a questionnaire are subsequently diagnosed as TIA after neurologist
19 assessment.¹⁴ Self-reported transient neurological symptoms in other community
20 based studies have low positive predictive value, with higher values only in studies in
21 outpatient populations (over 70%).^{13;14;22-24} This suggests that the use of screening to
22 identify possible past transient ischaemic attacks may generate unnecessary extra
23 strain on primary care and secondary TIA services with limited benefit.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51
52 Patients presenting with transient neurological symptoms present considerable
53 diagnostic dilemmas for primary care practitioners reflected in low rates of TIA
54 diagnosis confirmation in patients referred to UK TIA clinics (over 50% being for
55
56
57
58
59
60

1
2
3 non-TIA causes).^{6,25,26} Many symptoms of TIA are non-specific and occur in non-
4
5 vascular syndromes. Dizziness, ophthalmological problems, migraine, epilepsy, nerve
6
7 entrapment or psychological states are the commonest non-TIA diagnoses.²⁵⁻²⁹ Often,
8
9 however, no diagnosis can be determined.^{25,26} Scales such as the ABCD2² help
10
11 determine the urgency of TIA referral, but do not distinguish TIA from non-TIA
12
13 symptoms. Wilkinson et al. reported transient loss of speech and loss of sight to be
14
15 more reliable than limb weakness for neurologist diagnosis of TIA,¹⁴ while Hart et al.
16
17 found the strongest and most consistent relationship with subsequent stroke to be loss
18
19 of power in an arm.⁷ Other studies suggest that the presence of certain symptoms such
20
21 as headache, dizziness, loss of consciousness, memory loss, blurred vision,
22
23 generalised weakness, pain in limbs and seizures make the diagnosis of TIA less
24
25 likely.^{14,29,30}
26
27
28
29
30
31

32 Study limitations

34 The incidence of transient neurological symptoms ~~in the CFAS~~ was determined in
35
36 people without severe cognitive impairment, and may be an underestimate since
37
38 cognitive impairment can be a manifestation of vascular disease.^{31,32} Only three
39
40 transient neurological symptoms were reported in this study. Some symptoms of TIA
41
42 (e.g. posterior circulation or pure sensory symptoms) were not sought ~~in the CFAS~~.
43
44
45 The wording of questions to identify transient neurological symptoms may have
46
47 picked up some people who had symptoms lasting more than 24 hours. Such patients
48
49 are nevertheless likely to draw on TIA services for further assessment. In addition, it
50
51 was not possible to determine whether different transient neurological symptoms in a
52
53 participant occurred simultaneously or separately in time. The problem of recall bias
54
55 in these self-reports of transient symptoms needs to be considered. Questions were
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

designed to be easily comprehensible to the older population. However, the need to consider multiple criteria when responding to a question e.g. “sudden onset” and “less than a day”, may have led to difficulties in interpretation of the transient neurological symptoms questions for some participants. Finally, baseline and two year follow-up were carried out in the 1990s and changes in rates of vascular events may have occurred since then. While the age-specific incidence of stroke appears to be declining, it is not clear that the same is true of TIA.^{10;33;34} As well, this study is more recent than many studies estimating rates of transient neurological symptoms in the population, many of which have been carried out during the 1970’s or ‘80’s.¹²⁻¹⁴

Conclusion

In a large multi-centred community based study highly representative of the older population in the UK and conducted in the age group where TIAs are most common, we found a high prevalence and incidence of transient neurological symptoms. The incidence of such symptoms in the community is significantly greater than that of TIAs, ~~suggesting that potential demand for TIA clinics where a confirmation of TIA diagnosis is made by a specialist, might rise significantly in the future as the public becomes more sensitised to possible cerebrovascular symptoms, and primary care practitioners more aware of the potential benefits of rapid response to suspected TIA.~~ This highlights the need for adequate provision of TIA services and the potential importance of the development of valid diagnostic tools to assist the general practitioner and hospital doctor in better triage of people presenting with transient neurological symptoms.

ACKNOWLEDGEMENTS

We thank the MRC CFAS study group for data collection and management. We are also grateful to all respondents, their families and their primary care teams from across the country for their participation in ~~the~~ [MRC](#) CFAS.

COMPETING INTERESTS

"All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work."

FUNDING

The MRC CFAS Study has had funding by major awards from the Medical Research Council (MRC/G9901400) and Department of Health. NM was funded by a National Institute for Health Research (NIHR) Walport Clinical Lectureship in Primary Care Research. None of the sponsors influenced the design or conduct of the study or the analysis or interpretation of the findings. All researchers acted independently from funders in the design and carrying out of this study.

AUTHORS CONTRIBUTIONS

CB is Principal Investigator of the MRC CFAS Study. NM and GS contributed to analysis of data. All authors contributed to study design and intellectual input. All authors, external and internal, had full access to all of the data (including statistical

1
2
3 reports and tables) and can take responsibility for the integrity of the data and
4
5 accuracy of the data analysis.
6
7

8 9 10 **DATA SHARING**

11 Data sharing through application.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference List

- 1
2
3
4
5 (1) Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of
6 stroke after transient ischaemic attack or minor stroke: implications for public
7 education and organisation of services. *BMJ* 2004; 328(7435):326.
8
- 9
10 (2) Rothwell PM, Giles MF, Flossmann E, Lovelock CE, Redgrave JN, Warlow
11 CP et al. A simple score (ABCD) to identify individuals at high early risk of
12 stroke after transient ischaemic attack. *Lancet* 2005; 366(9479):29-36.
13
- 14 (3) Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O,
15 Redgrave JN et al. Effect of urgent treatment of transient ischaemic attack and
16 minor stroke on early recurrent stroke (EXPRESS study): a prospective
17 population-based sequential comparison. *Lancet* 2007; 370(9596):1432-1442.
18
- 19 (4) Department of Health. Department of Health. National Stroke Strategy. 2007.
20
- 21 (5) Department of Health. Stroke: Act F.A.S.T. awareness campaign. 2009.
22 Department of Health.
23
- 24 (6) Giles MF, Rothwell PM. Substantial underestimation of the need for
25 outpatient services for TIA and minor stroke. *Age Ageing* 2007; 36(6):676-
26 680.
27
- 28 (7) Hart CL, Hole DJ, Smith GD. The relation between questions indicating
29 transient ischaemic attack and stroke in 20 years of follow up in men and
30 women in the Renfrew/Paisley Study. *J Epidemiol Community Health* 2001;
31 55(9):653-656.
32
- 33 (8) Mant J, Wade DT, Winner S. Health care needs assessment: stroke. In:
34 Stevens A, Raftery J, Mant J, Simpson S, editors. Health care needs
35 assessment: the epidemiologically based needs assessment reviews. 2nd ed.
36 Oxford: Radcliffe Medical Press; 2004. 141-244.
37
- 38 (9) Orlandi G, Gelli A, Fanucchi S, Tognoni G, Acerbi G, Murri L. Prevalence of
39 stroke and transient ischaemic attack in the elderly population of an Italian
40 rural community. *Eur J Epidemiol* 2003; 18(9):879-882.
41
- 42 (10) Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE et al.
43 Population-based study of event-rate, incidence, case fatality, and mortality for
44 all acute vascular events in all arterial territories (Oxford Vascular Study).
45 *Lancet* 2005; 366(9499):1773-1783.
46
- 47 (11) Bos MJ, van Rijn MJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM.
48 Incidence and prognosis of transient neurological attacks. *JAMA* 2007;
49 298(24):2877-2885.
50
- 51 (12) Mules J, Henderson M, Kuller L. A population survey of symptoms suggestive
52 of transient ischemic attacks. *Stroke* 1971; 2(2):114-127.
53
54
55
56
57
58
59
60

- 1
2
3 (13) Toole JF, Lefkowitz DS, Chambless LE, Wijnberg L, Paton CC, Heiss G. Self-reported transient ischemic attack and stroke symptoms: methods and
4 baseline prevalence. The ARIC Study, 1987-1989. *Am J Epidemiol* 1996;
5 144(9):849-856.
6
7
8 (14) Wilkinson WE, Heyman A, Burch JG, Ostfeld A, Labarthe DR, Leviton A et
9 al. Use of a self-administered questionnaire for detection of transient cerebral
10 ischemic attacks: I. Survey of elderly persons living in retirement facilities.
11 *Ann Neurol* 1979; 6(1):40-46.
12
13 (15) Bots ML, van der Wilk EC, Koudstaal PJ, Hofman A, Grobbee DE. Transient
14 neurological attacks in the general population. Prevalence, risk factors, and
15 clinical relevance. *Stroke* 1997; 28(4):768-773.
16
17 (16) Howard VJ, McClure LA, Meschia JF, Pulley L, Orr SC, Friday GH. High
18 prevalence of stroke symptoms among persons without a diagnosis of stroke or
19 transient ischemic attack in a general population: the REasons for Geographic
20 And Racial Differences in Stroke (REGARDS) study. *Arch Intern Med* 2006;
21 166(18):1952-1958.
22
23 (17) van Wijk I, Kappelle LJ, van GJ, Koudstaal PJ, Franke CL, Vermeulen M et
24 al. Long-term survival and vascular event risk after transient ischaemic attack
25 or minor ischaemic stroke: a cohort study. *Lancet* 2005; 365(9477):2098-2104.
26
27 (18) Clark TG, Murphy MF, Rothwell PM. Long term risks of stroke, myocardial
28 infarction, and vascular death in "low risk" patients with a non-recent transient
29 ischaemic attack. *J Neurol Neurosurg Psychiatry* 2003; 74(5):577-580.
30
31 (19) Brayne C, McCracken C, Matthews FE. Cohort profile: the Medical Research
32 Council Cognitive Function and Ageing Study (CFAS). *Int J Epidemiol* 2006;
33 35(5):1140-1145.
34
35 (20) Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical
36 method for grading the cognitive state of patients for the clinician. *J Psychiatr*
37 *Res* 1975; 12(3):189-198.
38
39 (21) Copeland JR, Dewey ME, Griffiths-Jones HM. A computerized psychiatric
40 diagnostic system and case nomenclature for elderly subjects: GMS and
41 AGE-CAT. *Psychol Med* 1986; 16(1):89-99.
42
43 (22) Lasserson DS. Initial management of suspected transient cerebral ischaemia
44 and stroke in primary care: implications of recent research. *Postgrad Med J*
45 2009; 85(1006):422-427.
46
47 (23) Jones WJ, Williams LS, Meschia JF. Validating the Questionnaire for
48 Verifying Stroke-Free Status (QVSFS) by neurological history and
49 examination. *Stroke* 2001; 32(10):2232-2236.
50
51 (24) Wilson A, Potter J, Taub N, Moore A, Robinson T. The effectiveness of a
52 modified version of the Wilkinson questionnaire in screening for TIA and
53 minor stroke in the United Kingdom. *Age Ageing* 2005; 34(1):30-35.
54
55
56
57
58
59
60

- 1
2
3 (25) Murray S, Bashir K, Lees KR, Muir K, MacAlpine C, Roberts M et al.
4 Epidemiological aspects of referral to TIA clinics in Glasgow. *Scott Med J*
5 2007; 52(1):4-8.
6
7 (26) Martin PJ, Young G, Enevoldson TP, Humphrey PR. Overdiagnosis of TIA
8 and minor stroke: experience at a regional neurovascular clinic. *QJM* 1997;
9 90(12):759-763.
10
11 (27) Boysen G, Jensen G, Schnohr P. Frequency of focal cerebral transient
12 ischemic attacks during a 12 month period. The Copenhagen city heart study.
13 *Stroke* 1979; 10(5):533-534.
14
15 (28) Johnson SE, Skre H. Transient cerebral ischemic attacks in the young and
16 middle aged. A population study. *Stroke* 1986; 17(4):662-666.
17
18 (29) Amort M, Fluri F, Schafer J, Weisskopf F, Katan M, Burow A et al. Transient
19 ischemic attack versus transient ischemic attack mimics: frequency, clinical
20 characteristics and outcome. *Cerebrovasc Dis* 2011; 32(1):57-64.
21
22 (30) Dawson J, Lamb KE, Quinn TJ, Lees KR, Horvers M, Verrijth MJ et al. A
23 recognition tool for transient ischaemic attack. *QJM* 2009; 102(1):43-49.
24
25 (31) De Haan EH, Nys GM, van Zandvoort MJ. Cognitive function following
26 stroke and vascular cognitive impairment. *Curr Opin Neurol* 2006; 19(6):559-
27 564.
28
29 (32) Selnes OA, Vinters HV. Vascular cognitive impairment. *Nat Clin Pract*
30 *Neurol* 2006; 2(10):538-547.
31
32 (33) Dennis MS, Bamford JM, Sandercock PA, Warlow CP. Incidence of transient
33 ischemic attacks in Oxfordshire, England. *Stroke* 1989; 20(3):333-339.
34
35 (34) Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM et al.
36 Change in stroke incidence, mortality, case-fatality, severity, and risk factors
37 in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). *Lancet* 2004;
38 363(9425):1925-1933.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

COHORT PROFILE

Cohort Profile: The Medical Research Council Cognitive Function and Ageing Study (CFAS)[†]

Carol Brayne,^{1*} Cherie McCracken² and Fiona E Matthews³

Origin of the study

Global ageing is a recent phenomenon. Its potential impact on social and economic aspects of more affluent countries highlighted ageing as a sufficiently important issue towards which to direct resources. Discussion between the Department of Health, Medical Research Council, and experts from the scientific and medical communities resulted in the decision that brain changes, most particularly cognitive decline, dementia, and their relation to disability were key topics requiring investigation at the population level. This prompted a decision to invest in research into this area and a working group was convened, which included those with epidemiological and biostatistical expertise relevant to such investigation. Out of this working group a successful bid for the study now known as the MRC Cognitive Function and Ageing Study emerged.

Study design

The study is a six-centre multidisciplinary multiphased longitudinal design (see map, Figure 1). There are five identical sites and one with a different sampling and interview structure. This centre (Liverpool) was already funded at the time of the discussions noted above and thus started earlier than the other five centres.¹ The other five centres (Cambridgeshire, Gwynedd, Newcastle, Nottingham, and Oxford) were able to follow a standardized design and are referred to as the five identical sites. Their basic structure was a two-phase design with a screening interview followed by an assessment interview shortly afterwards, with a repeat at 2 years. The fieldwork began in 1991.² There are many additional features, which are more fully described on the website (see below).

The aims of the study

The aims of the study have evolved over its existence and cover a wide range including descriptive

epidemiology, neuropathology, policy, molecular epidemiology, and ethics.

The main descriptive epidemiological aims include (i) the estimation of the prevalence and incidence of cognitive decline and dementia, and geographical variation in those rates; (ii) the determination of the natural history of dementia, in particular the rate of progression of cognitive decline including the distribution of the interval between the identification of cognitive impairment and death, and (iii) the identification of factors associated with differing rates of cognitive decline and with the risk of dementia.

The principal neuropathological aim was to determine the contribution of different underlying pathologies to the rates of dementia and the geographic variation in these rates and to the burden of disability. Additional aims included to: (i) determine the prevalence and severity of pathological lesions in the brain of an unselected cohort of older people with and without cognitive impairment; (ii) determine the frequency of specific pathological diagnoses in people with cognitive impairment, and (iii) correlate severity of specific pathologies with patterns of cognition, function, and behaviour in life independently of clinical and pathological diagnostic categories.

The core aim related to policy was the evaluation of the degree of disability associated with cognitive decline and impairment, and the service needs this disability generates. These needs were to be compared with the needs generated by physical impairment. The study also sought to form the basis for longer-term studies of trends over time and by birth cohort of the prevalence and incidence of cognitive decline. In addition to these aims the breadth of the data collected has allowed the study to incorporate the investigation of expectation of life in various states of health, depression, and depressive symptomatology in the older population.

The DNA resource has been incorporated in a later phase of the study. The main molecular epidemiological aim has been to support genetics studies that have sought genes associated with all dementia, Alzheimer's disease, mixed and vascular dementia, cognitive impairment and decline.

A later aim of the study was to explore the ethical and legal aspects of brain donation within a population-based sample given changing perception surrounding organ donation.

The study also aimed to act as a core resource and provide a framework to support specific sub-studies in lone or joint centres. The Resource Implication Study^{3–9} utilized this framework to achieve the core policy aim (see above). Other

¹ Department of Public Health and Primary Care, Institute of Public Health, Cambridge University, Forvie Site, Robinson Way, Cambridge CB2 2SR, UK.

² Department of Psychiatry, University of Liverpool University, Clinical Dept Duncan Building Liverpool L69 3BX, UK.

³ MRC Biostatistics Unit, Institute of Public Health, Forvie Site, Robinson Way, Cambridge CB2 2SR, UK.

* Corresponding author. E-mail: Carol.Brayne@medschl.cam.ac.uk

[†] A full list of the study investigators and contributors is available on the website.



Figure 1 Map of Great Britain showing CFAS centres

sub-studies include the study of Healthy Ageing^{10–15} and the Network Study. This framework also extends to wider collaborations with CFAS centres contributing to European wide initiatives such as EURODEM¹⁶ and EURODEP.¹⁷

What does it cover?

Because the main study is focused on cognition and dementia it has collected the necessary dimensions of physical and mental health to arrive at a study diagnosis of dementia. It now has four major themes: (i) dementia (covering all aspects including cognition), (ii) depression, (iii) disability and healthy life expectancy, and (iv) health policy and health. In addition it has particular strengths in that it is one of the very few truly population based programmes with a donation programme—individuals in the study have indicated whether they wish to contribute to brain research through the donation of their brain after death (declaration of intention to donate).

Who is in the sample?

The first aim of the study was to estimate age-specific rates of prevalence of cognitive impairment and dementia among those aged 65 and over. The population is thus all

those aged 65 years and over on the index date for centre (1990, 1991), living within a specified geographical location. Background information on the demographics of the populations sampled was collected from the Office of Population Census and Surveys (OPCS), 1990–91 census now Office of National Statistics (ONS), to relate to regional and national data.

Family Health Service Authority (FHSA) lists were used as the sampling frame. The frame would be incomplete if eligible members of the population were not registered with a GP. However individuals in long-stay hospitals remain registered with their GP 2 years after institutionalization so sampling from FHSA lists ensured their inclusion. Each centre looked into the practices of long-stay hospitals in their area to confirm this. The FHSA list of individuals was used for sampling on a geographical basis. Each centre defined this area, and the study population was drawn from all those who were resident within it. Problems of inaccuracy, patients who died or moved away but were still on the FHSA list, were resolved by asking GP surgeries to check the lists. On this basis, a sample of sufficient size to yield 2500 interviews of individuals aged 65 years and over, stratified by age (equal numbers aged 65–74 and 75 plus) was chosen from the FHSA lists for each selected area (in Liverpool this was 5000 interviews stratified by sex and 5 year age band). The population is flagged at ONS for mortality and the database is updated continuously.

The follow-up has been determined by funding and the design of associated bolt-on studies. The main follow-up waves for the identical sites are captured in the audit trail shown in Figure 2, which shows the numbers for the main screen, assessment, 1 year follow-up and 2 year rescreen, new selection for assessment and further 1 year follow-up, 6 year follow-up of the assessed (with venepuncture), 8 year follow-up of those with intentions to donate, and 10 year follow-up of the total sample. In addition to this the main associated studies are the Resource Implication Study (4 centres—Cambridgeshire, Newcastle, Nottingham, Oxford), which followed those who provided care to the physically and cognitively frail at baseline, the ESRC funded Healthy Ageing Project, which interviewed in detail those who were not selected into the Resource Implication Study in Nottingham and Cambridgeshire, the Network Study conducted in Gwynedd and Liverpool to examine individuals' social networks, an embedded case-control study at 2 year incidence stage (Cambridgeshire), and the ongoing brain donation programme in all centres. This programme, in combination with the bloods taken at year 6 form the major components of the Biological Resource of the study.

Who is not in the sample?

Comprehensive analyses of those who were lost to follow-up have been conducted for all stages of the study. At baseline 19% of potential respondents refused, 6% had died, and 1% had moved out of the area. Similar percentages were found for all waves of the study. Individuals who had moved or refused had higher mortality than responders.¹⁸ CFAS has used this attrition for a detailed investigation of attrition effects in both short and longer time intervals.^{18,19}




Figure 2 Time frame of CFAS interviews (identical centres)

How, when, and which interviews were conducted?

All interviews were conducted in the respondent's place of residence, using portable computers with customized software. If the interviewer felt that the respondent was frail and tiring, or becoming agitated, the short 'priority mode' set of questions could be invoked manually. Screening interviews were undertaken by lay interviewers, recruited for the purpose and trained by both the local and national coordinator. Reliability checks were made by both the local and the national coordinator. Proxy screening interviews were conducted where an interview was not possible with the named participant, owing to, for example, extreme confusion or frailty. If after four attempts to contact, an interview was not arranged, the approach was abandoned. The screening of the entire sample took 2 years to complete.

The assessment (designed to be conducted 1 month after the screening interview) and annual (designed to be conducted

1 year after the screening interview) interviews were also undertaken using customized portable computers. These interviews were carried out by interviewers from professions allied to medicine, who had not undertaken the screening interview, also recruited and trained for the purpose. Interviewers did not know the outcome of the first interview. The interviews lasted from 45 to 90 min, again with a 'priority mode' route. The annual interview consisted of a combined screen and assessment, where information on changes since last interview was recorded. At the assessment and biannual follow-up interview permission was sought to approach and interview a relative or carer to ask for an objective account of the respondent's health and abilities.

Six years after the initial screening interview, all respondents in the assessed groups were interviewed using the combined screen and assessment interview and at the end of that interview signed permission was requested to take a sample of blood or saliva. Permission was also sought to access GP and hospital notes. At 8 years only those who had indicated an

intention to donate brain tissue were re-interviewed with the combined screen and assessment interview.

At 10 years all survivors from the responding group of the complete study were recontacted for interview and if they agreed were interviewed using the combined screen and assessment interview.

What is collected at different interviews?

The screening interview contains questions on residence, marital status, education and occupation, living circumstances, contact with friends and family, health and social care contact, self-reported physical health, instrumental activities of daily living and activities of daily living, cognitive measures (Mini Mental State Examination with augmentation), and medication.

The assessment interview is mainly the Geriatric Mental State Examination (GMS) adapted for CFAS.²⁰ This is a structured psychiatric interview, which collects sufficient information for algorithmic 'diagnosis' in the major psychiatric disorders of old age (dementia, depression, anxiety, and psychosis). This has been validated against clinical diagnosis and the instrument has been widely used in Europe and now forms part of the 10/66 international instrument. This interview has been augmented with questions from the CAMDEX (Cambridge Examination for Mental Disorders in the Elderly) including CAMCOG,²¹ the longer neuropsychological assessment. The relative or carer interview is mainly the History and Aetiological Schedule, the informant interview that accompanies the GMS.

The combined screen and assessment interview merges the two interviews but compresses some aspects of data collection. Complete versions of all the interviews including the interview questions and responses are available on the website.

The neuropathological assessment follows the standardized protocol of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD)²², with the exception that the neuropathologist is blind to the interview data. This covers in a semiquantitative form the main areas required for the assessment of neurodegenerative and cerebrovascular disorders. The forms are available on the website. The main genetic analyses have been on apoE and ACE.

Data collection in Liverpool was broadly similar to the other five sites except that the screening interview consisted of the GMS plus some of the screening interview questions listed above.

What has the study found?

The study has reported on prevalence and incidence of dementia, and lack of variation in these across the five identical sites.^{23–25} It has provided profiles of cognition for MMSE, extended MMSE, and CAMCOG, weighted back to the population.^{26,27} It has reported on risk for incident dementia including apoE and ACE.^{28–30} It has examined the relationship of cognition to mortality.^{18,31} It has reported on the mixed neuropathology found in the brains of the oldest old.³² In addition, the study has reported on a variety of impairments to healthy life in old age and their population burden.^{33–38}

The Resource Implication Study has provided data for examination of carer burden and the costs of care for physically and cognitively frail.^{3–9,39} The data have been used for projection forward, for these vulnerable groups and also for the costs of long-term care. Liverpool has published on the prevalence of dementia, depression, and neurosis, together with incidence of dementia and schizophrenia.^{40–43}

What are the main strengths?

The study is multisite and multidisciplinary. The population is truly representative with high response rates at each stage over diverse sites. Where there is no heterogeneity across sites the study is sufficiently large to provide indicative values for national estimates. The broad scope of measures has allowed the study to contribute to ageing research across a wide range of topics. There are repeat measures on cognition and function, which allows examination of trajectories. There are only two other population-based studies with brain donation in Europe.^{44,45} The study weighted the sample towards the over 75 age group at baseline, which has provided more robust data for the oldest old.

What are the main weaknesses?

It would be desirable to have higher response and lower drop out between waves, but analysis can adjust for loss between interviews. Blood taking and clinical assessment (including imaging) at baseline was not possible because of funding constraints, but venepuncture was included at year 6. The risk measures are self-report, using the available validated measures of the era.

Can I get hold of data?

The study actively encourages collaboration, and there are established mechanisms for approaching us via the themes mentioned above (see What does it cover?). Information is available on the website and also through contact with theme leads.

Where can I find out more?

The study website, www.cfas.ac.uk, configures information under themes, documentation, publications, and data. There is also a list of study contacts.

Acknowledgements

We are grateful to our respondents, their families, and their primary care teams. The study has only been possible because of the dedication of a large number of individuals over the years who are listed on the website. The MRC CFA Study has been supported by major awards from the Medical Research Council and the Department of Health. Thanks are also due to the Biological Resource Advisory Group for overseeing this aspect of study and to Lu Gao for preparation of the manuscript.

References

- 1 Saunders PA, Copeland JR, Dewey ME, Larkin BA, Scott A. Alpha: the Liverpool MRC Study of the incidence of dementia and cognitive decline. *Neuroepidemiology* 1992;**11**(suppl. 1):44–47.
- 2 Chadwick C. The MRC Multicentre Study of Cognitive Function and Ageing: a EURODEM incidence study in progress. *Neuroepidemiology* 1992;**11**(suppl. 1):37–43.
- 3 Buck D, Gregson BA, Bamford CH *et al*. Psychological distress among informal supporters of frail older people at home and in institutions. The Resource Implications Study Group of the MRC Cognitive Function and Ageing Study. *Int J Geriatr Psychiatry* 1997;**12**:737–44.
- 4 McNamee P, Gregson BA, Wright K, Buck D, Bamford CH, Bond J. Estimation of a multiproduct cost function for physically frail older people. *Health Econ* 1998;**7**:701–10.
- 5 McNamee P, Gregson BA, Buck D, Bamford CH, Bond J, Wright K. Costs of formal care for frail older people in England: the resource implications study of the MRC cognitive function and ageing study (RIS MRC CFAS). *Soc Sci Med* 1999;**48**:331–41.
- 6 Bond J, Farrow G, Gregson BA *et al*. Informal caregiving for frail older people at home and in long-term care institutions: who are the key supporters? *Health Soc Care Community* 1999;**7**:434–44.
- 7 Melzer D, McWilliams B, Brayne C, Johnson T, Bond J. Profile of disability in elderly people: estimates from a longitudinal population study. *BMJ* 1999;**318**:1108–11.
- 8 Psychological morbidity among informal caregivers of older people: a 2-year follow-up study. The Resource Implications Study Group of the MRC study of cognitive function and ageing (RIS MRC CFAS). *Psychol Med* 2000;**30**:943–55.
- 9 McNamee P, Bond J, Buck D. Costs of dementia in England and Wales in the 21st century. *Br J Psychiatry* 2001;**179**:261–66.
- 10 Solomou W, Richards MPM, Huppert FA, Brayne C, Morgan K. Divorce, current marital status and well-being in an elderly population. *Int J Law, Policy and the Family* 1998;**12**:321–342.
- 11 Huppert FA, Solomou W, O'Connor S, Morgan K, Sussams P, Brayne C. Aging and lymphocyte subpopulations: whole-blood analysis of immune markers in a large population sample of healthy elderly individuals. *Exp Gerontol* 1998;**33**:593–600.
- 12 Morgan K, Armstrong GK, Huppert FA, Brayne C, Solomou W. Healthy ageing in urban and rural Britain: a comparison of exercise and diet. *Age Ageing* 2000;**29**:341–48.
- 13 Huppert FA, Pinto EM, Morgan K, Brayne C. Survival in a population sample is predicted by proportions of lymphocyte subsets. *Mech Ageing Dev* 2003;**124**:449–51.
- 14 Huppert FA, Pinto E, Morgan K, MRC CFAS, Brayne C. Immune measures which predict 9-year survival in an elderly population sample. *Basic Biology and Clinical Impact of Immunosenescence, Advances in Cell Aging and Gerontology* 2003;**13**:17–28.
- 15 Pinto EM, Huppert FA, Morgan K, Mrc C, Brayne C. Neutrophil counts, monocyte counts and cardiovascular disease in the elderly. *Exp Gerontol* 2004;**39**:615–19.
- 16 Rocca WA, Hofman A, Brayne C *et al*. The prevalence of vascular dementia in Europe: facts and fragments from 1980–1990 studies. EURODEM-Prevalence Research Group. *Ann Neurol* 1991;**30**:817–24.
- 17 Copeland JR, Beekman AT, Braam AW *et al*. Depression among older people in Europe: the EURODEP studies. *World Psychiatry* 2004;**3**:45–49.
- 18 Matthews FE, Chatfield M, Freeman C, McCracken C, Brayne C. Attrition and bias in the MRC cognitive function and ageing study: an epidemiological investigation. *BMC Public Health* 2004;**4**:12.
- 19 Matthews FE, Chatfield M, Brayne C. An investigation of whether factors associated with short-term attrition change or persist over ten years: data from the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). *BMC Public Health* 2006;**6**:185.
- 20 Copeland JR, Dewey ME, Griffiths-Jones HM. A computerized psychiatric diagnostic system and case nomenclature for elderly subjects: GMS and AGE-CAT. *Psychol Med* 1986;**16**:89–99.
- 21 Huppert FA, Brayne C, Gill C, Paykel ES, Beardsall L. CAMCOG—a concise neuropsychological test to assist dementia diagnosis: socio-demographic determinants in an elderly population sample. *Br J Clin Psychol* 1995;**34**:529–41.
- 22 Mirra SS, Heyman A, McKeel D *et al*. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 1991;**41**:479–86.
- 23 Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study. The Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). *Psychol Med* 1998;**28**:319–35.
- 24 Matthews F, Brayne C. The incidence of dementia in England and Wales: findings from the five identical sites of the MRC CFA Study. *PLoS Med* 2005;**2**:e193.
- 25 Matthews FE, Dening T. Prevalence of dementia in institutional care. *Lancet* 2002;**360**:225–26.
- 26 Williams JG, Huppert FA, Matthews FE, Nickson J. Performance and normative values of a concise neuropsychological test (CAMCOG) in an elderly population sample. *Int J Geriatr Psychiatry* 2003;**18**:631–44.
- 27 Huppert FA, Cabelli ST, Matthews FE. Brief cognitive assessment in a UK population sample—distributional properties and the relationship between the MMSE and an extended mental state examination. *BMC Geriatr* 2005;**5**:7.
- 28 Yip AG, Brayne C, Matthews FE. Risk factors for incident dementia in England and Wales: The Medical Research Council Cognitive Function and Ageing Study. A population-based nested case-control study. *Age Ageing* 2006;**35**:154–60.
- 29 Yip AG, Brayne C, Easton D, Rubinsztein DC. An investigation of ACE as a risk factor for dementia and cognitive decline in the general population. *J Med Genet* 2002;**39**:403–06.
- 30 Yip AG, Brayne C, Easton D, Rubinsztein DC. Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population. *J Med Genet* 2002;**39**:639–43.
- 31 Neale R, Brayne C, Johnson AL. Cognition and survival: an exploration in a large multicentre study of the population aged 65 years and over. *Int J Epidemiol* 2001;**30**:1383–88.
- 32 Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). *Lancet* 2001;**357**:169–75.
- 33 Brayne C, Gao L, Matthews F. Challenges in the epidemiological investigation of the relationships between physical activity, obesity, diabetes, dementia and depression. *Neurobiol Aging* 2005;**26**(suppl. 1):6–10.
- 34 Jagger C, Matthews F. Gender differences in life expectancy free of impairment at older ages. *J Women Aging* 2002;**14**:85–97.
- 35 McGee MA, Johnson AL, Kay DW. The description of activities of daily living in five centres in England and Wales. Medical Research Council Cognitive Function and Ageing Study. *Age Ageing* 1998;**27**:605–13.
- 36 Melzer D, McWilliams B, Brayne C, Johnson T, Bond J. Socioeconomic status and the expectation of disability in old age: estimates for England. *J Epidemiol Commun Health* 2000;**54**:286–92.
- 37 Parker CJ, Morgan K, Dewey ME. Physical illness and disability among elderly people in England and Wales: the Medical Research Council Cognitive Function and Ageing Study. The Analysis Group. *J Epidemiol Commun Health* 1997;**51**:494–501.
- 38 Spiers NA, Matthews RJ, Jagger C *et al*. Diseases and impairments as risk factors for onset of disability in the older population in England and

- Wales: findings from the Medical Research Council Cognitive Function and Ageing Study. *J Gerontol A Biol Sci Med Sci* 2005;**60**:248–54.
- ³⁹ Comas-Herrera A, Wittenberg R, Pickard L, Knapp M, MRC-CFAS. Cognitive impairment in older people: its implications for future demand for services and costs. *Mental Health Research Review* 2001;**8**:37–38.
- ⁴⁰ Copeland JR, Chen R, Dewey ME *et al.* Community-based case-control study of depression in older people. Cases and sub-cases from the MRC-ALPHA Study. *Br J Psychiatry* 1999;**175**:340–47.
- ⁴¹ Copeland JR, McCracken CF, Dewey ME *et al.* Undifferentiated dementia, Alzheimer's disease and vascular dementia: age- and gender-related incidence in Liverpool. The MRC-ALPHA Study. *Br J Psychiatry* 1999;**175**:433–38.
- ⁴² Copeland JR, Dewey ME, Scott A *et al.* Schizophrenia and delusional disorder in older age: community prevalence, incidence, comorbidity, and outcome. *Schizophr Bull* 1998;**24**:153–61.
- ⁴³ Saunders PA, Copeland JR, Dewey ME *et al.* The prevalence of dementia, depression and neurosis in later life: the Liverpool MRC-ALPHA Study. *Int J Epidemiol* 1993;**22**:838–47.
- ⁴⁴ Polvikoski T, Sulkava R, Myllykangas L *et al.* Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study. *Neurology* 2001;**56**:1690–96.
- ⁴⁵ Xuereb JH, Brayne C, Dufouil C *et al.* Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. *Ann N Y Acad Sci* 2000;**903**:490–96.

For peer review only

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

- see below **

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
		(b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
		(c) Explain how missing data were addressed
		(d) If applicable, explain how loss to follow-up was addressed
		(e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
		(b) Indicate number of participants with missing data for each variable of interest
		(c) Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Report numbers of outcome events or summary measures over time
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
		(b) Report category boundaries when continuous variables were categorized

		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

STROBE checklist

Item	Reported on page
1(a)	1
1(b)	2
2	3,4
3	4
4	4,5
5	4-7
6 (a)	4,5
7	6
8	5,6
9	6
10	Described elsewhere - see references 1 and 2
11	6
12 (a)	6,7
12 (b)	6,7
12 (c)	6,7
12 (d)	6,7 – described elsewhere see references 1 and 2
12 (e)	N/A
13 (a)	7
13 (b)	7
13(c)	Described elsewhere – see reference 1
14 (a)	7
14(b)	see tables
14 (c)	6

1	15 cohort study	N/A
2	16(a)	see additional table
3	16(b)	N/A
4	16 (c)	N/A
5	17	7/8
6	18	7/8
7	19	11
8	20	9/10
9	21	9/10
10	22	13

Reference 1:

Brayne C, McCracken C, Matthews FE. Cohort profile: the Medical Research Council Cognitive Function and Ageing Study (CFAS). *Int J Epidemiol* 2006; 35(5):1140-1145.

Matthews FE, Chatfield M, Freeman C, McCracken C, Brayne C, MRC CFAS (2004), "Attrition and bias in the MRC cognitive function and ageing study: an epidemiological investigation." *BMC Public Health* 4:12